Robust Bayesian variable selection for gene-environment interactions by Ren, Jie et al.
Robust Bayesian variable selection for
gene-environment interactions
Jie Ren1,2, Fei Zhou2, Xiaoxi Li2, Shuangge Ma3, Yu Jiang4 and Cen Wu∗2
1 Department of Biostatistics, School of Medicine, Indiana University, Indianapolis, IN
2 Department of Statistics, Kansas State University, Manhattan, KS
3 Department of Biostatistics, Yale University, New Haven, CT
4 Division of Epidemiology, Biostatistics and Environmental Health, School of Public
Health, University of Memphis, Memphis, TN
∗ Corresponding author: Cen Wu, wucen@ksu.edu
Abstract
Gene-environment (G×E) interactions have important implications to elucidate the etiol-
ogy of complex diseases beyond the main genetic and environmental effects. Outliers and
data contamination in disease phenotypes of G×E studies have been commonly encountered,
leading to the development of a broad spectrum of robust regularization methods. Never-
theless, within the Bayesian framework, the issue has not been taken care of in existing
studies. We develop a fully Bayesian robust variable selection method for G×E interaction
studies. The proposed Bayesian method can effectively accommodate heavy–tailed errors
and outliers in the response variable while conducting variable selection by accounting for
structural sparsity. In particular, for the robust sparse group selection, the spike–and–slab
priors have been imposed on both individual and group levels to identify important main
and interaction effects robustly. An efficient Gibbs sampler has been developed to facilitate
fast computation. Extensive simulation studies and analysis of both the diabetes data with
SNP measurements from the Nurses’ Health Study and TCGA melanoma data with gene ex-
pression measurements demonstrate the superior performance of the proposed method over
multiple competing alternatives.
Keywords: Bayesian variable selection, Gene-environment interactions, MCMC, Robust
analysis, Sparse group selection
1 Introduction
Deciphering the genetic architecture of complex diseases is a challenging task, as it demands
the elucidation of the coordinated function of multiple genetic factors, their interactions, as
well as gene-environment interactions. How the genetic contributions to influence the varia-
tions in the disease phenotypes are mediated by the environmental factors reveals a unique
perspective of the disease etiology beyond the main genetic effects and their interactions (or
epistasis)1;2. Till now, G×E interaction analyses have been extensively conducted, especially
within the framework of genetic association studies3;4, to search for the important main and
interaction effects that are associated with the disease trait5.
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With the availability of a large amount of genetic factors, such as SNPs or gene ex-
pressions, G×E interactions are of high dimensionality even though the preselected environ-
mental factors are usually low dimensional. Therefore, variable selection has emerged as a
powerful tool to identify G×E interactions associated with the phenotypic traits6;7, and a
surging amount of G×E studies have recently been conducted along this line, especially with
regularization methods8.
A prominent trend among these studies is to incorporate robustness in regularized iden-
tification of main and interaction effects in order to accommodate data contamination and
heavy-tailed distributions in the disease phenotypes. Take the datasets analyzed in this arti-
cle for example. The disease outcomes of interest are weight from the Nurses’ Health Study
(NHS) and (log-transformed) Breslow’s depth from The Cancer Genome Atlas (TCGA) Skin
Cutaneous Melanoma (SKCM) data. We plot the two in Figure 1, where the long tails can
be clearly observed. In practice, such a heavy-tailed distribution is frequently encountered
and arise due to multiple reasons. For instance, some phenotypes have skewness in nature.
For the subjects’ recruited for the NHS, their ages are in the range from 41 to 68 as the
average age for the onset of type 2 diabetes is 459. The subjects’ weight among this age
group does have a right-skewed tendency. In addition, in the study of complex diseases such
as cancer, even patients of similar profiles may have different subtypes as rigorous accrual of
patients is usually not affordable. The data from the major disease subtype can be viewed
as being “contaminated” by other subtypes or outliers. As nonrobust approaches cannot
efficiently accommodate data contamination and long tailed distributions, which inevitably
leads to biased estimates and false identifications, the robust regularization methods have
thus been extensively developed for G×E studies7;8.
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Figure 1: Distribution of the outcome variables for the NHS (left) and SKCM (right) data.
Nevertheless, within the Bayesian framework, robust variable selection methods have not
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been investigated for gene-environment interactions by far. In fact, our literature search
indicates that only limited number of Bayesian variable selection methods have been devel-
oped for G×E studies, and none of them is robust8. Driven by the urgent need to conduct
robust Bayesian analysis, we propose robust Bayesian variable selection methods tailored
for interaction studies by adopting a Bayesian formulation of the least absolute deviation
(LAD) regression to accommodate data contamination and long-tailed distributions in the
phenotype. Such a formulation is a special case of the Bayesian quantile regression10. The
LAD loss has been a very popular choice for developing robust regularization methods for
data with structured sparsity, including networks11;12 and sparse group structure13. Its com-
putational convenience has been revealed within the Bayesian framework as efficient Gibbs
sampler can be constructed when the loss is combined with LASSO, group LASSO and
elastic net penalties14. Furthermore, following the strategy of bi–level selection from a non-
robust Bayesian setting15, we have developed the Bayesian LAD sparse group LASSO for
robust G×E interaction studies. The spike-and-slab priors have been imposed on both the
individual and group level to ensure the shrinkage of posterior estimates corresponding to
unimportant main and interaction effects to zero exactly. Such a prior leads to the real spar-
sity and is superior over Laplacian types of shrinkage in terms of identification and prediction
results16–18.
In this study, our objective is to tackle the challenging task of developing a fully Bayesian
robust variable selection method for G×E interactions, which has been well motivated from
the success of regularization methods (especially those robust ones) in G×E studies and
a lack of robust interaction analysis within the Bayesian framework. The significance of
the proposed study lies in the following aspects. First, it advances from existing Bayesian
G×E studies by incorporating robustness to accommodate data contamination and heavy-
tailed distributions in the disease phenotype. Second, on a broader scope, although robust
Bayesian quantile regression based variable selection has been proposed under LASSO, group
LASSO and elastic net, the more complicated sparse group (or bi-level) structure, which is
of particular importance in high dimensional data analysis in general19, has not been fully
understood yet. We are among the first to develop robust Bayesian sparse group LASSO for
bi-level selection. Third, unlike existing Bayesian regularized quantile regression methods
which build upon the priors under Laplacian type of shrinkage, we conduct efficient Bayesian
regularization on both the individual and group levels by borrowing strength from the spike-
and-slab priors, thus leading to better identification and prediction performance over the
competing alternatives, as demonstrated in extensive simulation studies and case studies
of NHS data with SNP measurements and TCGA melanoma data with gene expression
measurements. To facilitate reproducible research and fast computation using our MCMC
algorithms, we implement the proposed and alternative methods in C++, which are available
from an open source R package roben20 on CRAN.
2 Data and Model Settings
Use subscript i to denote the ith subject. Let (Xi, Yi, Ei,Wi), (i = 1, . . . , n) be independent
and identically distributed random vectors. Yi is a continuous response variable representing
the phenotypic trait. Xi is the p–dimensional vector of G factors. The environmental
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factors and clinical covariates are denoted as the k- and q-dimensional vectors Ei and Wi,
respectively. Considering the following model:
Yi =
q∑
t=1
αtWit +
k∑
m=1
θmEim +
p∑
j=1
γjXij +
p∑
j=1
k∑
m=1
ζjmEimXij + i
=
q∑
t=1
αtWit +
k∑
m=1
θmEim +
p∑
j=1
(
γjXij +
k∑
m=1
ζjmEimXij
)
+ i
=
q∑
t=1
αtWit +
k∑
m=1
θmEim +
p∑
j=1
(
U>ij βj
)
+ i,
(1)
where αt’s, θm’s, γj’s and ζjm’s are the regression coefficients for the clinical covariates,
environmental factors, genetic factors and G×E interactions, respectively. We define βj =
(γj, ζj1, . . . , ζjk)
> ≡ (βj1, . . . , βjL)> and Uij = (Xij, XijEi1 . . . , XijEik)> ≡ (Uij1, . . . , UijL)>,
where L = k + 1. The coefficient vector βj represents all the main and interaction effects
corresponding to the jth genetic measurement. The i’s are random errors. Without loss
of generality, we assume that the data have been properly normalized so that the intercept
can be omitted. Denote Ui = (U
>
i1 , . . . , U
>
ip)
>, α = (α1, . . . , αq)>, θ = (θ1, . . . , θk)> and
β = (β>1 , . . . , β
>
p )
>. The vector β is of length p × L. Then model (1) can be written in a
more concise form as
Yi = W
>
i α + E
>
i θ + U
>
i β + i (2)
2.1 Bayesian LAD Regression
The least absolute deviation (LAD) regression is well known for its robustness to long-tailed
distributions in response. For a Bayesian formulation of LAD regression, we assume that
i’s are i.i.d random variables from the Laplace distribution with density
f(i|ν) = ν
2
exp {−ν|i|} i = 1, . . . , n, (3)
where ν−1 is the scale parameter of the Laplace distribution. Let Y = (Y1, . . . , Yn)>. With
clinical covariates W = (W1, . . . ,Wn)
>, environment factors E = (E1, . . . , En)>, and ge-
netic main effects and G×E interactions U = (U1, . . . , Un)>, the likelihood function can be
expressed as
f(Y |W,E,U, α, θ, β, ν) =
n∏
i=1
ν
2
exp {−ν |Yi − µi|} , (4)
where µi = W
>
i α + E
>
i θ + U
>
i β.
Based on Kozumi and Kobayashi21, the Laplace distribution is equivalent to the mixture
of an exponential and a scaled normal distribution. Specifically, let z and u˜ be the standard
normal and exponential random variables, respectively. If a random variable  follows the
Laplace distribution with parameter ν, then it can be represented as follows
 = ν−1κ
√
u˜z, (5)
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where κ =
√
8 is a constant. Therefore, the response Yi can be rewritten as Yi = µi +
ν−1κ
√
u˜izi, where zi ∼ N(0, 1) and u˜i ∼ Exp(1). Let u = ν−1u˜. Then u follows the
exponential distribution Exp(ν−1). We thus have the following hierarchical representation
of the Laplace likelihood:
Yi = µi + ν
− 1
2κ
√
uizi,
ui|ν ind∼ ν exp (−νui) ,
zi
ind∼ N(0, 1).
This hierarchical representation allows us to express the likelihood function as a multivariate
normal distribution, which is critical to construct a Gibbs sampler for efficient sampling of
the regression coefficients corresponding to main and interaction effects robustly.
Remark : The Laplace distribution in Bayesian LAD regression can be treated as a special
case of the asymmetric Laplace distribution (ALD) in Bayesian quantile regression10;22. In
Bayesian quantile regression, we assume that i follows the asymmetric Laplace distribution
with density
f(i|τ, ν) = τ(1− τ)ν exp {−νρτ (i)} i = 1, . . . , n, (6)
where the check loss function is ρτ (i) = i {τ − I(i < 0)} for the τth quantile (0 < τ < 1).
Note that, when τ = 0.5, the ALD in (6) reduces to a symmetric Laplace distribution
defined in (3). Yu and Moyeed10 have shown that maximizing a likelihood function under
the asymmetric Laplace error distribution (6) is equivalent to minimizing the check loss
function in quantile regression. Kozumi and Kobayashi21 have proposed a Gibbs sampler for
Bayesian quantile regression based on a location-scale mixture representation of the ALD.
Specifically, with u˜ and z defined as above, the asymmetric Laplace error in (6) can be
represented as
 = ν−1ψz + ν−1κ
√
u˜z, (7)
where
ψ =
1− 2τ
τ(1− τ) and κ =
√
2
τ(1− τ) .
When τ = 0.5, we have ψ = 0 and κ =
√
8, and equation (7) reduces to the Laplace error in
(5).
2.2 Bayesian sparse group variable selection for G×E interactions
The proposed fully Bayesian sparse group variable selection is motivated by the following
considerations. In model (1), the coefficient vector βj corresponds to the main and interaction
effects with respect to the jth genetic variant. Whether the genetic variant is associated with
the phenotype or not can be determined by whether βj = 0. A zero coefficient vector suggests
that the variant does not have any effect on the disease outcome. If βj 6= 0, then a further
investigation on the presence of the main effect, the interaction or both is of interest, which
can be facilitated by examining the nonzero component in βj. Therefore, a tailored robust
Bayesian variable selection method for G×E studies should accommodate the selection on
both group (the entire vector of βj) and individual (each component of βj) levels at the same
time.
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In order to impose sparsity on both group and individual level to identify important main
and interaction effects, we conduct the decomposition of βj by following the reparameteri-
zation from15. Specifically, βj is defined as
βj = V
1
2
j bj,
where bj = (bj1, . . . , bjL)
> and V
1
2
j = diag {ωj1, . . . , ωjL} , ωjl ≥ 0 (l = 1, ..., L). To determine
whether the jth genetic variant has any effect at all, we conduct group-level selection on bj
by adopting the following multivariate spike–and–slab priors
bj|φbj ind∼ φbj NL (0, IL) + (1− φbj)δ0(bj),
φbj|pi0 ind∼ Bernoulli(pi0),
(8)
where IL is an identity matrix, δ0(bj) denotes a point mass at 0L×1 and pi0 ∈ [0, 1]. We
introduce a latent binary indicator variable φbj for each group j(j = 1, . . . , p) to tackle the
group–level selection. In particular, when φbj = 0, the coefficient vector bj has a point mass
density at zero and all predictors representing the main and interaction effects in the jth
group are excluded from the model, indicating that the jth genetic factor is not associated
with the phenotype. On the other hand, when φbj = 1, the components in coefficient vector
bj have non-zero values.
To further determine whether there is an important main genetic effect, G×E interaction
or both, we impose sparsity within the group j by assigning the following spike–and–slab
priors on each ωjl (j = 1, . . . , p and l = 1, . . . , L)
ωjl|φwjl ind∼ φwjl N+
(
0, s2
)
+ (1− φwjl)δ0(ωjl),
φwjl|pi1 ind∼ Bernoulli(pi1),
(9)
where N+ (0, s2) denotes a normal distribution, N (0, s2), truncated below at 0. When the
binary indicator variable φwjl = 0, ωjl is set to zero by the point mass function δ0(ωjl). Within
the jth group, when the component ωjl = 0, we have βjl = 0 and the corresponding Ujl is
excluded from the model, even when bj 6= 0. This implies that the jth genetic variant does
not have the main effect (if l=1) or the interaction effect with the (l − 1)th environment
factor (if l > 1). The βjl is non-zero if and only if the vector bj 6= 0 and the individual
element ωjl 6= 0.
In (8) and (9), pi0 and pi1 control the sparsity on the group and individual level, re-
spectively. Their values should be carefully tuned. Fixing their values at 0.5 makes the
prior essentially non-informative since equal prior probabilities are given to all the sub-
models. Instead of fixing pi0 and pi1, we assign conjugate beta priors pi0 ∼ Beta(a0, b0) and
pi1 ∼ Beta(a1, b1), which can automatically account for the uncertainty in choosing pi0 and pi1.
We fixed parameters a0 = b0 = a1 = b1 = 1, so that the priors are essentially non-informative.
For computation convenience, we assign a conjugate Inverse–Gamma hyperprior on s2
s2 ∼ Inv-Gamma(1, η)
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η is estimated with the Monte Carlo EM algorithm15;23. For the gth EM update,
η(g) =
1
Eη(g−1)
[
1
s2
|Y ] ,
where the posterior expectation of 1
s2
is estimated from the MCMC samples based on t(g−1).
To maintain conjugacy, we place a Gamma prior on ν,
ν ∼ Gamma(c, d).
where c and d are set to small values.
2.3 Gibbs sampler
The joint posterior distribution of all the unknown parameters conditional on data can be
expressed as
pi(α, θ, bj, ωjl,ν, ui, pi0, pi1, s
2|Y )
∝
n∏
i=1
(2piκ2ν−1ui)−
1
2 exp
−
(
Yi −W>i α− E>i θ −
∑p
j=1
(
U>ij βj
))2
2κ2ν−1ui

×
n∏
i=1
ν exp(−νui) νc−1 exp {−dν}
× exp
(
− 1
2
θ>Σ−1θ0 θ
)
exp
(
− 1
2
α>Σ−1α0α
)
×
p∏
j=1
(
pi0(2pi)
−L
2 exp
{
−1
2
b>j bj
}
I{bj 6=0} + (1− pi0)δ0(bj)
)
×
p∏
j=1
L∏
l=1
(
pi12(2pis
2)−
1
2 exp
{
−ω
2
jl
2s2
}
I{ωjl>0} + (1− pi1)δ0(ωjl)
)
× pia0−10 (1− pi0)b0−1
× pia1−11 (1− pi1)b1−1
× (s2)−2 exp(− η
s2
).
Define the coefficient vector without the jth group as β(j) = (β
>
1 , . . . , β
>
j−1, β
>
j+1, . . . , β
>
p ) and
the corresponding part of the design matrix as U(j). Likewise, define the coefficient vector
without the lth element in the jth group as β(jl) and the corresponding design matrix as
U(jl). Let l
b
j = p(bj 6= 0|rest), then the conditional posterior distribution of bj is a multivariate
spike–and–slab distribution:
bj|rest ∼ lbj NL(µbj , Σbj) + (1− lbj) δ0(bj), (10)
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where Σbj =
(
νκ−2
∑n
i=1 u
−1
i V
1
2
j UijU
>
ijV
1
2
j + IL
)−1
, µbj = Σbjνκ
−2∑n
i=1 u
−1
i V
1
2
j Uij y˜ij and
y˜ij = yi −W>i α− E>i θ − U>(j)β(j). The lbj can be derived as
lbj =
pi0
pi0 + (1− pi0)|Σbj |−
1
2 exp
{
−1
2
‖Σ
1
2
bj
νκ−2
∑n
i=1 u
−1
i V
1
2
j Uij y˜ij‖22
} .
The posterior distribution (10) is a mixture of a multivariate normal and a point mass at 0.
Specifically, at the gth iteration of MCMC, b
(g)
j is drawn from N(µbj , Σbj) with probability l
b
j
and is set to 0 with probability 1− lbj. If b(g)j is set to 0, we have φb(g)j = 0, which suggests that
the jth genetic variant is not associated with the phenotype at the gth iteration. Otherwise,
φ
b(g)
j = 1.
In addition to the multivariate spike–and–slab distribution on the group level, on the
individual level, the conditional posterior distribution of ωjl is also spike-and-slab. Let
lwjl = p(ωjl 6= 0|rest), we have
ωjl|rest ∼ lwjl N+(µωjl , σ2ωjl) + (1− lwjl)δ0(ωjl),
where σ2ωjl =
(
1
s2
+ νκ−2
∑n
i=1 u
−1
i U
2
ijlb
2
jl
)−1
, µωjl = σ
2
ωjl
νκ−2
∑n
i=1 u
−1
i bjlUijly˜ijl and y˜ijl =
yi −W>i α− E>i θ − U>(jl)β(jl). It can be shown that
lwjl =
pi1
pi1 + (1− pi1)12s(σ2ωjl)−
1
2 exp
{
−1
2
σ2ωjl
(
νκ−2
∑n
i=1 u
−1
i bjlUijly˜ijl
)2}[
Φ
(
µωjl
σωjl
)]−1 ,
where Φ(·) is the cumulative distribution function of the standard normal random variable.
At the gth iteration, the value of φ
w(g)
jl can be determined by whether the ω
(g)
jl is set to 0 or
not. Recall that φ
w(g)
jl = 0 implies that the jth genetic variant does not have the main effect
(if l=1) or the interaction effect with the (l − 1)th E factor (if l > 1).
The full conditional distribution for ui is Inverse-Gaussian:
ui|rest ∼ Inverse-Gaussian(µui , λui),
where the shape parameter λui = 2ν, mean parameter µui =
√
2κ2
(Yi−y˜i)2 and y˜i = Yi−W>i α−
E>i θ − U>i β.
With the conjugate Inverse–Gamma prior, the posteriors of s2 is still an Inverse–Gamma
distribution
s2|rest ∼ Inv-Gamma
(
1 +
1
2
∑
j,l
I{ωjl 6=0}, η +
1
2
∑
j,l
ω2jl
)
.
With conjugate Beta priors, pi0 and pi1 have beta posterior distributions
pi0|rest ∼ Beta
(
a0 +
p∑
j=1
I{bj 6=0}, b0 +
p∑
j=1
I{bj=0}
)
,
pi1|rest ∼ Beta
(
a1 +
∑
j,l
I{ωjl 6=0}, b1 +
∑
j,l
I{ωjl=0}
)
.
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Last, the full conditional distribution for ν is Gamma distribution
ν|rest ∼ Gamma (sν , rν) ,
where the shape parameter sν = c +
3n
2
and the rate parameter rν = d +
∑n
i=1 ui +
(2κ2)−1
∑n
i=1 u
−1
i y˜i
2. Under our prior setting, conditional posterior distributions of all un-
known parameters have closed forms by conjugacy. Therefore, efficient Gibbs sampler can
be constructed for the posterior distribution.
We term the proposed robust Bayesian sparse group variable selection with spike and slab
priors as RBSG–SS, with direct competitors RBG–SS, RBL–SS and ones without spike and
slab priors: RBSG, RBG and RBL. With the non-robust counterpart, there are 12 methods
under comparison, which have all been implemented in the C++ based R package roben20
available from CRAN. It is worth mentioning that besides RBSG–SS, RBG–SS, RBL–SS
and RBSG have also been proposed for the first time. A summary of all the methods is
provided below.
2.4 A summary of proposed and alternative methods
All the methods under comparison can be grouped according to three criteria: with or with-
out robustness, with or without spike-and-slab priors, and the types of structured sparsity
(individual-, group- and bi-level) accommodated through variable selection. We first de-
scribe the robust Bayesian methods with spike-and-slab priors: RBSG–SS, RBG–SS and
RBL–SS, which have all been proposed for the first time. Among them, RBSG–SS is the
“golden” method developed for conducting robust sparse group variable selection for G×E
interactions with spike-and-slab priors on both the group and individual levels. Besides,
RBG–SS and RBL–SS are robust Bayesian group level and individual level selection with
spike–and–slab priors, respectively. The spike–and–slab prior has only been imposed on the
group level in RBG–SS. Compared to RBSG–SS, it does not induce within group sparsity.
On the other hand, RBL–SS conducts individual-level selection without accounting for group
structure. An immediate family of robust methods related to the three are RBSG, RBG and
RBL, which do not adopt spike–and–slab priors and cannot shrink coefficients corresponding
to the main and interaction effects to zero exactly. While RBG and RBL can be directly
derived based on Li et al.14, RBSG, robust Bayesian sparse group selection, has not been
investigated in existing studies so far.
We have also included six non-robust methods for comparison. Among them, BSG–SS,
BG–SS and BL–SS are the non–robust counterparts of RBSG–SS, RBG–SS and RBL–SS,
respectively. In particular, the BSG–SS conducts (non–robust) Bayesian sparse group selec-
tion with spike-and-slab priors on group and individual level simultaneously, while variable
selection has only been conducted on group (individual) level through RBG–SS (RBL–SS)
under the spike–and–slab priors. In addition, BSG, BG and BL can be viewed as the bench-
marks without incorporating spike–and–slab priors corresponding to BSG–SS, BG–SS and
BL–SS. They can also be considered as the non–robust counterpart corresponding to RBSG,
RBG and RBL. All the six non–robust alternatives can be readily derived based on existing
studies.
For clarification, we list all the methods under comparison in Table 4 in the Appendix.
Our contribution includes developing the 4 robust Bayesian variable selection approaches,
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RBSG–SS, RBG–SS, RBL–SS and RBSG among the first time. For all the rest of the
approaches, a modification to the methods from the references provided in Table 4 by in-
cluding clinical covariates is necessary. Otherwise, these methods cannot be adopted for a
direct comparison with the four newly developed ones.
3 Simulation
We comprehensively evaluate the proposed and alternative methods through simulation stud-
ies. Under all the settings, the responses are generated from model (1) with n = 500, q =
3, p = 100 and k = 5, which leads to a total dimension of 608 with 105 main effects, 500
interactions and 3 additional clinical covariates. The genetic main effects and G×E inter-
actions form 100 groups with group size L = 6. We consider six error distributions for i’s:
N(0, 1)(Error 1), Laplace(µ,b) with the mean µ = 0 and the scale parameter b = 2 (Error
2), 10%Laplace(0,1) + 90%Laplace(0,
√
5) (Error 3), 90%N(0,1) + 10%Cauchy(0, 1) (Error
4), t-distribution with 2 degrees of freedom (t(2)) (Error 4), LogNormal(0,1) (Error 5). All
of them are heavy-tailed distributions except the first one.
We assess the performance in terms of identification and prediction accuracy. For
methods incorporating spike–and–slab priors, we consider the median probability model
(MPM)15;24 to identify important effects. In particular, for the proposed RBSG–SS, we de-
fine φjl = φ
b
jφ
w
jl for the lth predictor in the jth group. At the gth MCMC iterations, this
predictor is included in the model if the indicator φ
(g)
jl is 1. Suppose we have collected G
posterior samples from the MCMC after burn-ins, then the posterior probability of including
the lth predictor from the jth group in the final model is
pjl = pˆi(φjl = 1|y) = 1
G
G∑
g=1
φ
(g)
jl , j = 1, . . . , p and l = 1, . . . , L. (11)
A higher posterior inclusion probability pjl can be interpreted as a stronger empirical evi-
dence that the corresponding predictor has a non-zero coefficient and is associated with the
phenotype. The MPM model is defined as the model consisting of predictors with at least
1
2
posterior inclusion probability. When the goal is to select a single model, Barbieri and
Berger24 recommend using MPM because of its optimal prediction performance. Meanwhile,
the 95% credible interval (95%CI)25 is adopted for methods without spike–and–slab priors.
Prediction performance is evaluated using the mean prediction errors on an independently
generated testing dataset under the same data generating model over 100 replicates. For all
robust approaches, the prediction error is defined as mean absolute deviations (MAD). MAD
can be computed as 1
n
∑n
i=1 |yi − yˆi|. The prediction error for non–robust ones is defined as
the mean squared error (MSE), i.e., 1
n
∑n
i=1 (yi − yˆi)2.
The G factors are simulated in the following 4 examples(settings). In the first example,
a gene expression matrix with n = 500 and p = 100 has been generated from a multivari-
ate normal distribution with marginal mean 0, marginal variance 1 and an auto-regression
correlation structure (ρ = 0.3). In the second example, the single-nucleotide polymorphism
(SNP) data are obtained by dichotomizing the gene expression values (from the first setting)
at the 1st and 3rd quartiles, with the 3–level (0,1,2) for genotypes (aa,Aa,AA) respectively.
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In the third setting, the SNP data are simulated under a pairwise linkage disequilibrium
(LD) structure. Let the minor allele frequencies (MAFs) of two neighboring SNPs with
risk alleles A and B be r1 and r2, respectively. The frequencies of four haplotypes are as
pAB = r1r2+δ, pab = (1−r1)(1−r2)+δ, pAb = r1(1−r2)−δ, and paB = (1−r1)r2−δ, where
δ denotes the LD. Assuming Hardy-Weinberg equilibrium and given the allele frequency
for A at locus 1, we can generate the SNP genotype (AA, Aa, aa) from a multinomial
distribution with frequencies (r21, 2r1(1 − r1), (1 − r1)2). The genotypes at locus 2 can be
simulated according to the conditional genotype probability matrix in Cui et al.26. We have
δ = rp
√
r1(1− r1)r2(1− r2) with MAFs 0.3 and pairwise correlation rp = 0.6. In the last
example, we consider a more practical correlation structure by extracting the first 100 SNPs
from the NHS data analyzed in the case study, so the correlation is based on the real data.
For each simulation replicate, we randomly sample 500 subjects from the dataset.
For E factors, five continuous variables are generated from a multivariate normal distri-
bution with marginal mean 0, marginal variance 1 and AR correlation structure with ρ = 0.5.
We then dichotomize one of them at 0 to create a binary E factor. Besides, we simulate three
clinical covariates from a multivariate normal distribution and AR correlation structure with
ρ = 0.5, and dichotomize one of them at 0 to create a binary variable.
For the clinical covariates and environmental main effects, the coefficients αt’s and θm’s
are generated from Uniform[0.8, 1.5]. For genetic main effect and G×E interactions, we
randomly selected 25 βjl’s in 9 groups to have non-zero values that are generated from
Uniform[0.3, 0.9]. All other βjl’s are set to zeros.
We have collected the posterior samples from the Gibbs sampler running 15,000 iterations
while discarding the first 7,500 samples as burn-ins. The Bayesian estimates are calculated
using the posterior medians. Simulation results for the gene expression data in Example 1 are
tabulated in Table (1) and (2). We can observe that the performance of methods that adopt
spike–and–slab priors in Table (1) is consistently better than methods without spike–and–
slab priors in Table (2). Although, methods without spike–and–slab priors have slightly lower
FPs than their counterparts with spike–and–slab priors under some error distributions, they
tend to have much lower TPs and higher prediction errors under all the error distributions.
For example, under Error2, RBSG identifies 14.48(SD 2.04) out of the 25 true positives,
much lower than the true positives of 21.66(SD 1.72) from RBSG–SS. Meanwhile, its false
positives 0.64(SD 0.85) is only slightly lower than the FP of RBSG–SS (1.32(SD 1.33)). The
prediction error of RBSG, 2.57 with a SD of 0.11, is also inferior than that of the RBSG–SS
(2.15(SD 0.10)). Such an advantage can also be observed by comparing other methods in
Table (1) with their counterparts (without spike–and–slab priors) from Table (2).
Among all the methods with spike–and–slab priors, as shown in Table (1), the proposed
RBSG–SS has the best performance in both identification and prediction in the presence
of data contamination and heavy–tailed errors. Under the mixture Laplace error (Error 3),
RBSG–SS identifies 21.28(SD 2.24) true positives, with a small number of false positives,
1.48(SD 1.34). RBG–SS has a true positive of 24.80(SD 0.73), however, the number of false
positives, 30.64(SD 4.23), is much higher. This is due to the fact that RBG–SS only conducts
group level selection and does not impose the within-group sparsity. Compared to RBSG–
SS, RBL–SS ignores the group structure, leading to fewer true positives of 18.14(SD2.68).
In terms of prediction, RBSG–SS has the smallest L1 error, 2.29(0.12), among all the 3
robust methods with spike–and–slab priors. Although the difference in prediction error
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Table 1: Simulation results in Example 1. (n, q, k, p) = (500, 2, 5, 100). mean(sd) of true
positives (TP), false positives (FP) and prediction errors (Pred) based on 100 replicates.
RBSG–SS RBG–SS RBL–SS BSG–SS BG–SS BL–SS
Error 1 TP 24.97(0.18) 25.00(0.00) 24.93(0.25) 24.97(0.18) 25.00(0.00) 24.93(0.25)
FP 1.30(1.24) 29.60(2.42) 1.30(1.44) 0.47(0.68) 29.00(0.00) 0.43(0.73)
Pred 0.83(0.03) 0.86(0.03) 0.84(0.04) 1.07(0.07) 1.13(0.07) 1.08(0.08)
Error 2 TP 21.66(1.72) 24.84(0.55) 18.58(2.14) 19.98(1.95) 24.58(0.86) 15.54(2.04)
FP 1.32(1.33) 30.96(4.27) 1.62(1.64) 1.82(1.53) 30.98(4.83) 0.92(0.94)
Pred 2.15(0.10) 2.17(0.09) 2.24(0.12) 9.32(0.97) 8.98(0.79) 10.09(1.08)
Error 3 TP 21.28(2.24) 24.80(0.73) 18.14(2.68) 19.00(2.61) 24.40(1.09) 14.24(2.39)
FP 1.48(1.34) 30.64(4.23) 1.42(1.63) 2.04(1.73) 30.20(4.73) 1.18(1.16)
Pred 2.29(0.12) 2.32(0.11) 2.41(0.12) 11.11(1.12) 10.59(0.95) 12.02(1.12)
Error 4 TP 23.80(1.30) 24.93(0.37) 21.80(1.94) 16.20(6.45) 21.83(5.24) 12.53(5.79)
FP 0.53(0.86) 29.47(2.56) 0.20(0.41) 3.73(4.61) 35.77(23.92) 1.93(2.49)
Pred 1.50(0.14) 1.52(0.13) 1.53(0.14) 12.48(6.56) 12.34(7.27) 13.35(6.72)
Error 5 TP 24.33(0.76) 25.00(0.00) 22.93(1.20) 22.93(1.26) 25.00(0.00) 18.00(2.17)
FP 0.26(0.45) 29.00(0.00) 0.13(0.35) 4.30(3.40) 34.80(8.11) 1.23(1.55)
Pred 1.16(0.10) 1.18(0.10) 1.18(0.10) 4.75(1.24) 4.78(1.23) 5.18(1.34)
between RBSG–SS and RBG–SS is not distinct, considering the much smaller number of
false positive main and interaction effects, we can fully observe the advantage of RBSG–SS
over RBG–SS in prediction.
Moreover, a cross–comparison between the robust and non–robust methods further demon-
strates the necessity of developing robust Bayesian methods. For instance, under the error
of t distribution with 2 degrees of freedom (Error 4), RBSG–SS has identified 23.80(SD
1.30) true main and interaction effects with only 0.53(SD 0.86) false positives. Its direct
non–robust competitor, BSG–SS, leads to a true positive of 16.20(SD 6.45) with 3.73(SD
4.61) false effects. The superior performance of RBSG–SS over the other two non–robust
methods, BG–SS and BL–SS, is also clear. Although a comparison between the prediction
errors of robust and non–robust methods is not feasible as the two are computed under the
L1 and least square errors, the identification results convincingly suggest the advantage of
robust methods over non-robust ones,
Similar patterns have been observed in Table 6, 7, 8, 9, 10 and 11 for Examples 2, 3 and
4, respectively, in the Appendix. Overall, based on the investigations over all the methods
through comprehensive simulation studies, we can establish the advantage of conducting
robust Bayesian bi–level selection incorporating spike–and–slab priors.
We demonstrate the sensitivity of RBSG–SS for variable selection to the choice of the
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Table 2: Simulation results in Example 1. (n, q, k, p) = (500, 2, 5, 100). mean(sd) of true
positives (TP), false positives (FP) and prediction errors (Pred) based on 100 replicates.
RBSG RBG RBL BSG BG BL
Error 1 TP 21.87(1.38) 24.67(0.76) 21.97(1.40) 22.93(1.34) 24.93(0.37) 23.07(1.23)
FP 2.63(1.94) 55.33(15.76) 3.07(2.35) 2.43(1.77) 83.47(20.07) 11.20(4.34)
Pred 1.15(0.05) 1.37(0.06) 1.15(0.05) 1.73(0.12) 2.29(0.19) 2.21(0.17)
Error 2 TP 14.48(2.04) 23.06(1.96) 14.42(2.12) 15.18(2.06) 24.02(1.48) 15.48(2.30)
FP 0.64(0.85) 32.26(7.41) 0.74(0.88) 2.20(1.55) 85.78(20.06) 14.06(4.41)
Pred 2.57(0.11) 2.85(0.13) 2.57(0.11) 12.43(1.15) 15.92(1.68) 16.55(1.69)
Error 3 TP 13.74(2.65) 22.52(2.38) 13.80(2.66) 14.30(2.70) 23.92(1.37) 14.62(2.69)
FP 0.68(0.68) 34.24(8.93) 0.80(0.83) 2.74(1.48) 97.40(19.78) 15.96(4.30)
Pred 2.71(0.12) 3.00(0.14) 2.71(0.12) 14.36(1.35) 18.52(1.70) 19.25(1.84)
Error 4 TP 16.90(3.12) 21.83(3.04) 16.90(3.36) 11.70(5.86) 20.70(5.74) 12.07(5.44)
FP 0.33(0.48) 27.97(8.48) 0.27(0.45) 3.10(2.64) 88.50(28.58) 14.83(5.52)
Pred 1.85(0.15) 2.10(0.17) 1.85(0.15) 16.25(9.88) 22.78(17.05) 24.20(18.91)
Error 5 TP 16.26(2.28) 23.42(2.01) 16.42(2.16) 13.80(3.37) 23.24(2.25) 14.24(3.05)
FP 0.32(0.62) 29.38(7.54) 0.32(0.65) 3.00(2.14) 94.72(27.12) 16.26(4.84)
Pred 2.20(0.14) 2.49(0.17) 2.21(0.14) 15.94(4.43) 20.73(5.12) 21.66(5.48)
hyper–parameters for pi0, and pi1 in the Appendix. The results are tabulated in Table 5,
showing that the MPM model is insensitive to different specification of the hyper-parameters.
Following Li et al.25, we assess the convergence of the MCMC chains by the potential scale
reduction factor (PSRF)27;28. PSRF values close to 1 indicate that chains converge to the
stationary distribution. Gelman et al.29 recommend using PSRF≤ 1.1 as the cutoff for
convergence, which has been adopted in our study. We compute the PSRF for each parameter
and find the convergence of all chains after the burn-ins. For the purpose of demonstration,
Figure 2 shows the pattern of PSRF the first five groups of coefficients in Example 1 under
Error 2. The figure clearly shows the convergence of the proposed Gibbs sampler.
4 Real Data Analysis
4.1 Nurses’ Health Study (NHS) data
Nurses’ Health Study (NHS) is one of the largest investigations into the risk factors for major
chronic diseases in women. As part of the Gene Environment Association Studies initiative
(GENEVA), the NHS provides SNP genotypes data as well as detailed information on dietary
and lifestyle variables. Obesity level is one of the most important risk factors for Type 2
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diabetes mellitus (T2D), a chronic disease due to both genetic and environmental factors. In
this study, we analyze the NHS type 2 diabetes data to identify main and interaction effects
associated with obesity. We use weight as the response and focus on SNPs on chromosome
10. We consider five environment factors, including the total physical activity (act), glycemic
load (gl), cereal fiber intake (ceraf), alcohol intake (alcohol) and a binary indicator of whether
an individual has a history of high cholesterol (chol). All these environmental exposures have
been suggested to be associated with obesity and diabetes30. In addition, we include three
clinical covariates: height, age and a binary indicator of whether an individual has a history
of hypertension (hbp). In NHS study, about half of the subjects are diagnosed of type 2
diabetes and the other half are controls without the disease. We only use health subjects in
this study. After cleaning the data through matching phenotypes and genotypes, removing
SNPs with minor allele frequency (MAF) less than 0.05 or deviation from Hardy–Weinberg
equilibrium, the working dataset contains 1732 subjects with 35099 SNPs.
For computational convenience prescreening can be conducted to reduce For computa-
tional convenience prescreening can be conducted to reduce the feature space to a more
attainable size for variable selection. For example, Li et al.25 and Wu et al.31 use the single
SNP analysis to filter SNPs in a GWA study before downstream analysis. In this study, we
use a marginal linear model with weight as the response variable to evaluate the penetrance
effect of a variant under the environmental exposure. The marginal linear model uses a group
of genetic main effect and G×E interactions corresponding to a SNP as the predictors, and
test whether this SNP has any effect, main or G×E interaction. The SNPs with p-values
less than a certain cutoff (0.001) for any effect, main or interaction, from the test are kept.
253 SNPs pass the screening.
The proposed approach RBSG-SS identifies 22 main SNP effects and 45 G×E interac-
tions. The detailed estimation results are provided in Table 12 in the Appendix. We observe
that the proposed method identifies main and interaction effects of SNPs with important
implications in obesity. For example, two important SNPs, rs6482836 and rs10741150, that
located within gene DOCK1 are identified. DOCK1 (Dedicator Of Cytokinesis 1) has been
reported as a putative candidate for obesity related to adiponectin and triceps skinfold by
previous studies32;33. RBSG-SS identifies the main effect of rs6482836 and its interaction
with the E factor act. Physical activity plays an important role in the prevention of over-
weight and obese34. This result suggests that the expression level of DOCK1 in an individual
may influence the effect of physical activity in obesity prevention. RBSG-SS also identifies
the interaction between rs10741150 and the E factor chol, suggesting that the effect of choles-
terol level can be mediated by DOCK1. Interestingly, a previous study has shown that the
expression level of DOCK5, an important paralog of DOCK1, is increased in individuals
exposed to a diet high in saturated fatty acids35. Our results provide more evidence of the
importance of DOCK1 in diet-induced obesity. Another example is the SNP rs11196539,
located within gene NRG3. NRG3(Neuregulin 3) has been found to be associated with both
the basal metabolic rate (BMR) and body mass index (BMI)36. RBSG-SS identifies its
interaction with the E factors, gl and alcohol. Both glycemic load and alcohol intake are
important dietary variables associated with obesity. The continued intake of high-glycemic
load meals leads to an increased risk of obesity37. The increasing alcohol consumption is as-
sociated with a decline in body mass index in women38, however, heavy drinking can increase
risk of the metabolic syndrome39. Our results suggest that further investigation of NRG3
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may help explain the mechanism of the effects of glycemic load and alcohol intake on obesity.
For the environment main effects, two E factors, chol and gl, have positive coefficients, and
the other three, act, ceraf and alcohol, have negative coefficients, which are consistent with
findings in the previous literature.
In addition to the proposed approach, we also conduct analysis using the alternatives
RBL–SS, BSG–SS and BL–SS. As other alternative methods show inferior performance in
simulation, they are not considered in real data analysis. Detailed estimation results are
provided in Table 13, 14 and 15 in the Appendix. In Table 3, we provide the numbers of
identified main and interaction effects with pairwise overlaps, to show the difference in terms
of identification between the proposed method and the others. To further investigate the
biological similarity of the identified genes, we conduct the Gene Ontology (GO) analysis.
We can find an obvious difference between the proposed RBSG–SS and the three alternatives.
The GO analysis results are provided in Figure 3.
With real data, it is difficult to assess the selection accuracy objectively. The prediction
performance may provide additional information to the selection results. Following Yan and
Huang40 and Li et al.25, we refit the models identified by RBSG–SS and RBL–SS using
the robust Bayesian Lasso, and refit the models selected by BSG–SS and BL–SS using the
Bayesian Lasso. For robust methods, the prediction mean absolute deviations (PMAD) are
computed based on the posterior median estimates. The PMADs are 8.64 and 8.88 for
RBSG–SS and RBL–SS, respectively. The proposed method outperforms the competitors.
For non-robust methods, the prediction mean squared errors, or PMSEs, are 128.39 and
137.77 for BSG–SS and BL–SS, respectively. Overall, the superior performance of RNSG–
SS over the alternatives can be observed.
4.2 TCGA skin cutaneous melanoma data
In this case study, we analyze the Cancer Genome Atlas (TCGA) skin cutaneous melanoma
(SKCM) data. TCGA is a collaborative effort supported by the National Cancer Institute
(NCI) and the National Human Genome Research Institute (NHGRI), and has published
high quality clinical, environmental, as well as multi–omics data. For this study, we use the
level-3 gene expression data of SKCM downloaded from the cBio Cancer Genomics Portal41.
Our goal is to identify genes that have genetic main effect or G×E interaction effects on
the Breslow’ thickness, an important prognostic variable for SKCM42. The log-transformed
Breslow’s depth is used as the response variable and four E factors are considered, age,
AJCC pathologic tumor stage, gender and Clark level. Data are available on 294 subjects
and 20,531 gene expressions. We adopt the same screening method used in the first case
study to select 109 genes for further analysis.
The proposed approach RBSG–SS identifies 16 main SNP effects and 32 G×E interac-
tions. The detailed estimation results are available from Table 16 in the Appendix. One
important gene identified is CXCL6 (C-X-C Motif Chemokine Ligand 6), a chemokine with
neutrophil chemotactic and angiogenic activities. It has been reported that CXCL6 plays
an important role in melanoma growth and metastasis43. RBSG-SS identifies its main effect
and its interactions with E factors, stage and Clark level. This suggests that CXCL6 can
have different effects at different stages of melanoma. Another important finding is the gene
MAGED4, one of member in MAGE(Melanoma-associated antigen) family. MAGE family
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contains genes that are highly attractive targets for cancer immunotherapy44. MAGED4 has
been found to be an potential target for glioma immunotherapy45. RBSG-SS identifies the
main effect of MAGED4 and its interaction with the E factor tumor stage, suggesting that
MAGED4 may also play an important role in SKCM and its effect may change over different
tumor stages. For the main effects of the E factors, Clark level and tumor stage have positive
coefficients, and age and gender have negative coefficients, which match observations in the
literature.
Analysis is also conducted via the three alternative methods, and the results are sum-
marized in Table 3. Detailed estimation results are provided in Table 17, 18 and 19 in the
Appendix. Again, the proposed RBSG–SS identifies different sets of main and interaction
effects from the rest. We further investigate the biological similarity of the identified genes
by GO analysis (Figure 3), which suggests an obvious difference. Prediction performance is
also evaluated. The PMADs are 0.69 and 0.83 for RBSG–SS and RBL–SS, respectively. The
proposed approach again has better prediction performance than RBL–SS. The PMSEs are
0.93 and 1.05 for BSG-SS and BL-SS, respectively. Combined, the RBSG–SS outperforms
the alternatives.
Table 3: The numbers of main G effects and interactions identified by different approaches
and their overlaps.
NHS Main G effects Interactions
RBSG-SS RBL-SS BSG-SS BL-SS RBSG-SS RBL-SS BSG-SS BL-SS
RBSG-SS 22 20 16 13 45 21 17 10
RBL-SS 29 20 16 39 14 14
BSG-SS 29 25 34 22
BL-SS 27 42
SKCM Main G effects Interactions
RBSG-SS RBL-SS BSG-SS BL-SS RBSG-SS RBL-SS BSG-SS BL-SS
RBSG-SS 16 10 14 13 32 11 18 10
RBL-SS 17 12 14 33 15 24
BSG-SS 22 15 29 14
BL-SS 20 33
5 Discussion
In this study, we have developed robust Bayesian variable selection methods for gene-
environment interaction studies. The robustness of our methods comes from Bayesian formu-
lation of LAD regression. In G×E studies, the demand for robustness arises in heavy-tailed
distribution/ data contamination in both the response and predictors, as well as model
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misspecification. We have focused on the first case, which is frequently encountered in prac-
tice. Investigations of the robust Bayesian methods accommodating the other two cases are
interesting and will be pursued in the future.
Recently, penalization has emerged as a power tool for dissecting G×E interactions8.
Our literature review suggests that Bayesian variable selection methods, although tightly
related to penalization, has not been fully explored for interaction analyses, let alone the
robust ones. We are among the first to conduct robust G×E analysis within the Bayesian
framework. The proposed Bayesian LAD sparse group LASSO are not only specifically
tailored for G×E studies, and but also generally applicable for problems incorporating the
bi-level structure in a broader context, such as simultaneously selection of prognostic genes
and pathways46;47. The spike-and-slab priors have been incorporated to further improve
identification and prediction performances. As a byproduct, the Bayesian LAD LASSO and
group LASSO, both with spike-and-slab priors, have also been investigated for the first time.
The computational feasibility of the Gibbs samplers is guaranteed by the R package roben,
with the core modules of the MCMC algorithms developed in C++.
In G×E studies, the form of interaction effects can be linear, nonlinear, and both lin-
ear and nonlinear, resulting in parametric13;48;49, nonparametric25;50;51 and semiparametric
variable selection methods31;52;53 to dissect G×E interactions, respectively. The proposed
study can be potentially generalized to these studies within robust Bayesian framework. For
example, variable selection for multiple semiparametric G×E studies can be formulated as
a combination of individual and group level selection problem, where the robust Bayesian
methods based on sparse group, group and individual level selection are directly applicable.
The proposed robust Bayesian framework has paved the way for the future investigations.
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A Summary of methods.
Table 4: Summary of the proposed and alternative methods.
Methods Reference
Robust
RBSG-SS Robust Bayesian sparse group selection
with spike–and–slab priors
proposed for the first time
RBG-SS Robust Bayesian group selection with
spike–and–slab priors
proposed for the first time
RBL-SS Robust Bayesian Lasso with spike–and–slab
priors
proposed for the first time
RBSG Robust Bayesian sparse group selection proposed for the first time
RBG Robust Bayesian group Lasso Li et al. (2010)14
RBL Robust Bayesian Lasso Li et al. (2010)14
Non-robust
BSG-SS Bayesian sparse group Lasso with
spike–and–slab priors
Xu and Ghosh (2015)15
BG-SS Bayesian group Lasso with spike–and–slab
priors
Xu and Ghosh (2015)15
Zhang et al. (2014)54
BL-SS Bayesian Lasso with spike–and–slab priors Xu and Ghosh (2015)15
Zhang et al. (2014)54
BSG Bayesian sparse group Lasso Xu and Ghosh (2015)15
BG Bayesian group Lasso Kyung et al. (2010)55
BL Bayesian Lasso Park and Casella (2008)23
Note: The models in the references are modified to be applicable to G×E settings.
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B Hyper-parameters sensitivity analysis
We demonstrate the sensitivity of RBSG-SS for variable selection to the choice of the hyper-
parameters for pi0, and pi1. We consider five different Beta priors: (1) Beta(0.5, 0.5) which
is a U-shape curve between (0, 1); (2) Beta(1, 1) which is a essentially a uniform prior; (3)
Beta(2, 2) which is a quadratic curve; (4) Beta(1, 5) which is highly right-skewed; (5) Beta(5,
1) which is highly left-skewed. As a demonstrating example, we use the same setting of Ex-
ample 1 to generate data under the Error 2. Table 5 shows the identification performance
of the median thresholding model (MPM) with different Beta priors. For all choices of Beta
priors, the MPM model is very stable. Also, RBSG-SS correctly identifies most of the true
effects with low false positives in all cases. Therefore, we simply use Beta(1, 1) as the prior
for pi0, and pi1 in this study.
Table 5: Sensitivity analysis for RBSG-SS using Example 1. mean(sd) of true positives (TP),
false positives (FP) and prediction errors (Pred) based on 100 replicates.
TP FP Pred
Beta(0.5, 0.5) 21.31(1.67) 1.71(1.50) 2.19(0.11)
Beta(1, 1) 21.66(1.72) 1.32(1.33) 2.17(0.10)
Beta(2, 2) 21.13(2.10) 1.47(1.16) 2.18(0.10)
Beta(1, 5) 20.82(1.71) 1.38(1.30) 2.17(0.10)
Beta(5, 1) 21.58(1.75) 2.22(1.52) 2.19(0.09)
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C Assessment of the convergence of MCMC chains
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Figure 2: Potential scale reduction factor (PSRF) against iterations for the first five groups
of coefficients in Example 1. Black line: the PSRF. Red line: the threshold of 1.1. The βˆj1
to βˆj6 represent the six estimated coefficients for the main and interaction effects in the jth
group, (j = 0, . . . , 5), respectively.
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D Additional simulation results
Table 6: Simulation results in Example 2. (n, q, k, p) = (500, 2, 5, 100). mean(sd) of true
positives (TP), false positives (FP)and prediction errors (Pred) based on 100 replicates.
RBSG-SS RBG-SS RBL-SS BSG-SS BG-SS BL-SS
Error 1 TP 24.87(0.35) 25.00(0.00) 24.53(0.51) 24.83(0.38) 25.00(0.00) 24.53(0.51)
FP 1.63(1.16) 31.40(3.38) 2.30(1.86) 1.13(1.04) 29.20(1.10) 0.60(0.85)
Pred 0.85(0.03) 0.86(0.03) 0.86(0.03) 1.09(0.06) 1.13(0.06) 1.10(0.07)
Error 2 TP 22.23(1.76) 24.67(0.76) 19.23(1.72) 19.97(1.63) 24.47(0.90) 15.27(1.91)
FP 1.90(1.30) 35.73(7.83) 2.10(1.40) 2.33(1.42) 34.13(7.44) 1.73(1.39)
Pred 2.24(0.14) 2.18(0.11) 2.38(0.16) 10.21(1.27) 9.13(0.94) 11.30(1.83)
Error 3 TP 21.50(1.48) 25.00(0.00) 17.43(2.13) 18.73(2.02) 25.00(0.00) 13.10(1.54)
FP 2.13(1.14) 35.20(6.77) 1.90(1.37) 2.90(1.71) 34.00(6.88) 1.37(0.96)
Pred 2.39(0.18) 2.29(0.11) 2.52(0.22) 12.46(1.67) 10.40(0.94) 13.04(1.35)
Error 4 TP 23.58(1.49) 25.00(0.00) 21.04(2.29) 15.94(5.34) 23.18(3.50) 12.08(4.60)
FP 0.80(0.93) 30.32(3.27) 0.78(1.07) 7.46(27.02) 53.50(58.05) 3.56(8.91)
Pred 1.85(0.16) 1.82(0.13) 1.92(0.17) 25.65(55.13) 25.63(67.60) 30.67(87.77)
Error 5 TP 24.12(1.00) 25.00(0.00) 21.82(1.90) 18.04(3.64) 24.24(1.88) 13.12(2.99)
FP 0.90(1.02) 29.48(1.64) 0.82(0.90) 2.72(1.75) 36.12(12.21) 1.48(1.25)
Pred 1.81(0.13) 1.82(0.12) 1.89(0.15) 14.85(6.53) 12.87(5.94) 15.19(6.43)
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Table 7: Simulation results in Example 2. (n, q, k, p) = (500, 2, 5, 100). mean(sd) of true
positives (TP), false positives (FP) and prediction errors (Pred) based on 100 replicates.
RBSG RBG RBL BSG BG BL
Error 1 TP 24.20(0.61) 25.00(0.00) 24.23(0.57) 24.33(0.61) 25.00(0.00) 24.30(0.60)
FP 2.93(1.86) 54.80(17.34) 3.30(1.97) 1.87(1.61) 56.20(10.30) 5.77(2.56)
Pred 1.14(0.05) 1.32(0.06) 1.15(0.05) 1.74(0.12) 2.13(0.14) 2.01(0.15)
Error 2 TP 14.00(2.27) 22.20(2.33) 13.63(2.66) 13.70(2.29) 23.63(1.61) 14.20(1.97)
FP 0.60(0.85) 31.40(12.07) 0.83(1.05) 1.33(1.18) 62.77(24.90) 8.80(4.54)
Pred 2.57(0.13) 2.77(0.14) 2.58(0.14) 12.18(1.15) 14.42(1.40) 14.91(1.43)
Error 3 TP 12.40(2.03) 22.47(1.17) 12.27(1.87) 12.43(1.77) 23.20(1.49) 13.37(2.13)
FP 0.57(0.77) 29.33(5.54) 0.60(0.93) 1.47(1.31) 59.80(13.17) 8.17(3.04)
Pred 2.69(0.11) 2.86(0.11) 2.69(0.10) 13.59(1.05) 16.32(1.46) 16.93(1.60)
Error 4 TP 15.98(2.92) 23.04(2.78) 16.10(3.12) 10.20(5.31) 20.52(5.81) 11.08(5.00)
FP 0.26(0.53) 27.36(6.21) 0.30(0.65) 2.34(3.56) 65.04(30.70) 9.38(6.26)
Pred 2.19(0.16) 2.35(0.16) 2.21(0.17) 26.27(53.26) 34.08(78.47) 34.95(79.04)
Error 5 TP 16.48(2.69) 23.48(1.58) 16.30(2.63) 11.96(3.66) 22.26(3.70) 12.70(3.50)
FP 0.32(0.59) 28.72(5.89) 0.34(0.59) 1.40(1.21) 62.34(20.52) 8.34(3.77)
Pred 2.20(0.14) 2.41(0.14) 2.20(0.13) 15.79(5.97) 18.90(6.61) 19.53(6.65)
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Table 8: Simulation results in Example 3. (n, q, k, p) = (500, 2, 5, 100). mean(sd) of true
positives (TP), false positives (FP)and prediction errors (Pred) based on 100 replicates.
RBSG-SS RBG-SS RBL-SS BSG-SS BG-SS BL-SS
Error 1 TP 24.00(0.91) 25.00(0.00) 22.13(1.57) 24.33(0.66) 25.00(0.00) 22.83(1.37)
FP 1.85(1.46) 33.40(5.21) 1.87(1.36) 1.27(1.34) 29.60(1.83) 0.77(1.04)
Pred 0.86(0.03) 0.86(0.03) 0.89(0.03) 1.11(0.07) 1.13(0.07) 1.17(0.10)
Error 2 TP 17.63(2.37) 24.73(0.69) 14.37(2.54) 15.00(2.32) 23.73(1.46) 11.00(1.95)
FP 2.50(1.41) 33.27(5.14) 2.67(1.99) 2.60(1.43) 30.67(6.69) 1.87(1.53)
Pred 2.33(0.12) 2.15(0.10) 2.40(0.17) 10.37(1.01) 9.01(0.81) 10.71(0.94)
Error 3 TP 17.23(1.77) 24.80(0.61) 14.47(2.21) 15.10(2.29) 23.67(1.77) 11.03(1.38)
FP 2.27(1.78) 32.20(6.94) 1.63(1.43) 2.13(1.70) 30.93(5.48) 1.17(1.34)
Pred 2.39(0.13) 2.24(0.10) 2.45(0.13) 11.98(1.45) 10.32(1.04) 12.37(1.41)
Error 4 TP 23.63(1.19) 24.67(0.92) 20.13(2.19) 15.07(4.69) 22.67(3.68) 11.40(4.01)
FP 1.30(1.12) 29.13(2.67) 1.17(0.95) 3.37(1.88) 29.93(9.48) 2.37(1.97)
Pred 1.48(0.13) 1.45(0.11) 1.55(0.14) 12.66(12.40) 10.10(8.77) 12.75(11.83)
Error 5 TP 24.80(0.48) 25.00(0.00) 23.57(1.43) 20.30(2.83) 24.87(0.51) 15.87(2.32)
FP 0.33(0.55) 29.60(1.83) 0.40(1.04) 3.00(1.66) 32.93(5.86) 2.33(1.63)
Pred 1.19(0.10) 1.21(0.10) 1.21(0.11) 6.055(1.77) 5.47(1.73) 6.54(1.75)
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Table 9: Simulation results in Example 3. (n, q, k, p) = (500, 2, 5, 100). mean(sd) of true
positives (TP), false positives (FP) and prediction errors (Pred) based on 100 replicates.
RBSG RBG RBL BSG BG BL
Error 1 TP 21.27(1.17) 25.00(0.00) 21.30(1.06) 22.23(0.94) 25.00(0.00) 22.13(1.28)
FP 1.97(1.56) 45.40(11.68) 2.03(1.56) 1.23(1.33) 43.60(10.41) 3.37(2.03)
Pred 1.08(0.04) 1.21(0.05) 1.07(0.04) 1.57(0.12) 1.87(0.13) 1.79(0.13)
Error 2 TP 8.40(1.87) 18.67(2.68) 8.27(2.02) 8.07(1.57) 20.73(2.65) 8.73(2.15)
FP 0.43(0.63) 20.73(4.93) 0.57(0.77) 0.67(0.66) 36.27(11.59) 3.83(2.05)
Pred 2.44(0.13) 2.58(0.13) 2.44(0.12) 10.97(1.05) 12.78(1.31) 13.02(1.33)
Error 3 TP 8.43(2.18) 16.70(3.29) 8.70(2.00) 7.97(2.04) 18.60(3.07) 8.27(1.78)
FP 0.33(0.71) 17.70(4.60) 0.43(0.73) 0.60(0.72) 33.60(10.63) 3.70(2.34)
Pred 2.54(0.11) 2.69(0.12) 2.55(0.11) 12.33(1.15) 14.30(1.40) 14.55(1.40)
Error 4 TP 13.77(2.18) 21.20(2.06) 13.67(2.04) 9.67(3.74) 20.60(4.79) 9.77(3.76)
FP 0.43(0.63) 22.80(3.98) 0.57(0.63) 1.03(1.13) 38.00(12.21) 4.47(2.50)
Pred 1.73(0.12) 1.85(0.13) 1.73(0.13) 11.78(9.05) 13.94(11.84) 14.22(12.41)
Error 5 TP 19.10(1.86) 24.87(0.73) 19.10(1.60) 15.27(2.94) 24.07(1.70) 15.07(2.88)
FP 0.20(0.48) 31.13(5.96) 0.23(0.57) 1.10(1.16) 43.93(11.82) 3.83(2.21)
Pred 1.45(0.08) 1.61(0.09) 1.46(0.08) 6.13(1.13) 7.19(1.24) 7.16(1.29)
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Table 10: Simulation results in Example 4. (n, q, k, p) = (500, 2, 5, 100). mean(sd) of true
positives (TP), false positives (FP) and prediction errors (Pred) based on 100 replicates.
RBSG-SS RBG-SS RBL-SS BSG-SS BG-SS BL-SS
Error 1 TP 24.93(0.37) 25.00(0.00) 24.93(0.25) 25.00(0.00) 25.00(0.00) 24.90(0.31)
FP 1.33(0.99) 30.60(3.84) 1.47(1.25) 1.00(1.02) 29.20(1.10) 0.33(0.61)
Pred 0.84(0.02) 0.88(0.02) 0.85(0.03) 1.10(0.04) 1.20(0.06) 1.11(0.05)
Error 2 TP 20.80(2.65) 23.60(1.47) 17.24(2.96) 18.58(3.46) 23.04(1.64) 14.08(3.26)
FP 1.32(1.22) 30.76(4.93) 1.66(1.29) 1.98(1.53) 27.72(5.49) 1.42(1.25)
Pred 2.25(0.11) 2.22(0.08) 2.37(0.12) 10.32(1.25) 9.53(0.75) 11.43(1.20)
Error 3 TP 20.56(2.73) 23.69(1.38) 16.53(3.20) 17.56(3.49) 22.80(1.65) 12.67(3.39)
FP 1.40(1.30) 30.04(5.46) 1.78(1.82) 1.76(1.28) 27.60(5.24) 1.22(1.43)
Pred 2.38(0.13) 2.35(0.10) 2.51(0.16) 12.04(1.40) 11.12(0.96) 13.32(1.44)
Error 4 TP 24.60(0.93) 24.67(0.92) 23.77(1.57) 20.10(6.38) 22.27(5.10) 15.63(6.69)
FP 0.40(0.56) 29.13(2.97) 0.47(0.73) 1.83(1.90) 28.13(9.22) 1.17(1.15)
Pred 1.48(0.09) 1.52(0.09) 1.51(0.11) 11.54(6.94) 11.33(6.95) 12.64(6.74)
Error 5 TP 23.16(1.68) 24.96(0.28) 19.60(2.14) 15.64(3.76) 23.44(1.83) 11.60(2.75)
FP 1.08(1.16) 29.16(1.33) 0.72(0.83) 2.20(1.83) 30.56(7.43) 1.48(1.43)
Pred 1.56(0.14) 1.53(0.13) 1.63(0.15) 10.98(5.80) 9.45(5.38) 11.38(6.03)
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Table 11: Simulation results in Example 4. (n, q, k, p) = (500, 2, 5, 100). mean(sd) of true
positives (TP), false positives (FP) and prediction errors (Pred) based on 100 replicates.
RBSG RBG RBL BSG BG BL
Error 1 TP 21.47(1.87) 24.40(1.07) 21.67(1.81) 22.70(1.64) 24.87(0.51) 22.53(1.85)
FP 3.17(2.51) 56.00(20.03) 3.33(2.59) 2.30(1.66) 66.33(14.04) 6.57(2.62)
Pred 1.26(0.06) 1.44(0.07) 1.27(0.06) 2.40(0.27) 2.83(0.24) 2.75(0.30)
Error 2 TP 9.08(2.54) 19.38(3.12) 9.20(2.60) 9.68(2.41) 20.82(2.93) 10.80(2.65)
FP 0.78(0.86) 30.30(10.26) 0.84(0.89) 2.18(1.48) 65.94(19.60) 8.62(3.38)
Pred 2.67(0.08) 2.89(0.09) 2.67(0.09) 13.54(0.87) 16.38(1.19) 16.87(1.27)
Error 3 TP 8.51(2.31) 18.71(3.37) 8.62(2.33) 9.02(2.33) 20.60(2.76) 10.58(2.50)
FP 0.56(0.69) 25.29(7.94) 0.56(0.66) 1.87(1.36) 56.87(15.55) 7.38(2.91)
Pred 2.79(0.11) 3.00(0.12) 2.79(0.12) 15.34(1.29) 18.66(1.69) 19.30(1.88)
Error 4 TP 13.30(3.32) 21.93(2.72) 13.47(3.33) 10.93(4.30) 20.97(4.76) 11.97(4.43)
FP 0.50(0.57) 29.07(9.28) 0.40(0.50) 1.70(1.39) 60.03(20.56) 7.90(3.92)
Pred 2.03(0.12) 2.22(0.12) 2.03(0.12) 15.20(7.98) 18.61(12.19) 19.41(13.39)
Error 5 TP 14.38(2.64) 22.36(2.22) 14.40(2.70) 10.12(3.53) 20.84(3.74) 10.56(3.39)
FP 0.30(0.58) 25.16(4.36) 0.22(0.46) 0.88(1.12) 36.52(12.60) 3.70(2.57)
Pred 1.84(0.15) 1.99(0.17) 1.84(0.15) 11.23(5.54) 13.02(5.80) 13.18(5.90)
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E Estimation results for data analysis
Table 12: Analysis of the NHS T2D data using RBSG-SS.
SNP Gene∗ chol act gl ceraf alcohol
3.503 -3.447 0.752 -3.364 -2.639
rs10741150 DOCK1 -0.948
rs10765059 TCERG1L -0.531 0.877
rs10786611 RF00019 0.668 0.723 0.530
rs10884466 RNA5SP326 -0.466 0.643
rs10885423 NRG3 -0.715
rs10886442 GRK5 0.805
rs11196539 NRG3 -0.608 -0.801
rs11198590 CACUL1 -0.494 0.994 -0.687
rs11259039 FRMD4A 1.016
rs1194657 THAP12P3 0.798
rs1219508 RPS15AP5 -0.742
rs12265854 SLC16A12 0.397
rs12414552 TCERG1L 0.667 0.470 0.585 -0.690
rs12767723 SLC25A18P1 0.820 -0.515
rs12772559 TACR2 0.938 0.510
rs12774333 LRMDA -0.599
rs12775160 FOXI2 -0.651 -0.501 0.647
rs16916794 SLC39A12 -0.552 0.511 0.455
rs16920092 PLXDC2 -0.843
rs17094114 GFRA1 -0.615
rs2492664 OR6L1P 0.695 -0.737
rs2784767 PLAC9 -0.540
rs2814322 GRID1 -0.830
rs3740063 ABCC2 -0.966
rs3763722 LARP4B 0.332 -1.156 0.866
rs4411238 PRKG1 0.537
rs4578341 CHST15 -0.822 0.602
rs4747517 ITIH5 -1.468 0.920
rs4749926 IL2RA -0.840 -0.815
rs4917817 PYROXD2 -0.624 0.594
rs4918904 XRCC6P1 0.997
rs6482836 DOCK1 -0.957 1.067
rs7070789 GPAM -1.245 -0.791
rs7072255 ANTXRLP1 0.800
rs7077721 SNRPD2P1 0.858 0.774
rs7896554 NACAP2 0.840 -0.630 -0.565
rs7897847 LGI1 0.962
rs870753 CFAP58 -0.783
Continued on the next page
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Table 12: Continued from the previous page.
SNP Gene∗ chol act gl ceraf alcohol
rs881726 GFRA1 1.001
∗ Genes that SNPs belong to or are the closest to.
Table 13: Analysis of the NHS T2D data using RBL-SS.
SNP Gene∗ chol act gl ceraf alcohol
1.354 -0.430 -0.778 -2.424 -4.000
rs1041168 PLPP4 0.463
rs10741150 DOCK1 -1.126
rs10786611 RF00019 0.632
rs10794069 ADAM12 0.524
rs10824802 MBL2 0.553
rs10884466 RNA5SP326 -0.439 0.503
rs10885423 NRG3 -1.060
rs10886047 MIR3663HG -0.410
rs10886442 GRK5 1.087
rs10998780 ATP5MC1P7 0.150
rs11003665 RNA5SP318 0.632
rs11013740 KIAA1217 0.852
rs11196539 NRG3 -0.624
rs11198590 CACUL1 -0.628
rs11202221 BMPR1A 0.815
rs11259039 FRMD4A 1.021
rs11595123 AKR1E2 1.079
rs11813505 KIAA1217 1.301
rs1194657 THAP12P3 0.663
rs1219508 RPS15AP5 -0.886
rs12265854 SLC16A12 0.596
rs12269237 RF00017 0.884
rs12414552 TCERG1L 0.594
rs12414627 PNLIPRP1 -0.551
rs12767723 SLC25A18P1 0.962
rs12772559 TACR2 0.906
rs12774333 LRMDA -0.449
rs12775160 FOXI2 -0.560
rs1573137 SORCS3 0.615
rs16916794 SLC39A12 -0.803 0.528
rs16920092 PLXDC2 -0.655
rs17094114 GFRA1 -0.563
rs2291314 PLPP4 0.536
rs2420979 TACC2 -1.091
Continued on the next page
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Table 13: Continued from the previous page.
SNP Gene∗ chol act gl ceraf alcohol
rs2492664 OR6L1P 0.655 -0.363
rs2664339 RNU6-543P -0.501
rs2666236 IATPR 0.689
rs2784767 PLAC9 -0.452 0.730
rs2814322 GRID1 -0.806
rs2842129 DYNC1I2P1 -0.662
rs2900814 SNRPD2P1 -0.643
rs3740063 ABCC2 -0.885
rs3763722 LARP4B 1.036
rs4411238 PRKG1 0.399
rs4578341 CHST15 -0.582 0.479
rs4747009 LRRC20 0.710
rs4747517 ITIH5 -0.905
rs4749926 IL2RA -0.607
rs4752432 PLPP4 0.725
rs4917817 PYROXD2 -0.506
rs4934762 PCAT5 -0.560
rs6482836 DOCK1 -0.709
rs7070789 GPAM -0.820
rs7072255 ANTXRLP1 0.811
rs7077721 SNRPD2P1 0.702
rs7894809 PCGF5 0.501
rs7896554 NACAP2 0.850 -0.953
rs7897847 LGI1 0.929
rs7903853 FRMD4A -1.185
rs7920351 TCERG1L -0.713
rs881726 GFRA1 0.675
rs943213 DOCK1 -0.939
∗ Genes that SNPs belong to or are the closest to.
Table 14: Analysis of the NHS T2D data using BSG-SS.
SNP Gene∗ chol act gl ceraf alcohol
2.045 -2.049 -2.204 -1.796 -4.436
rs1041168 PLPP4 0.638
rs10765059 TCERG1L 0.709
rs10786611 RF00019 0.773 0.556
rs10829671 EBF3 -0.505
rs10884466 RNA5SP326 -0.563 0.625
rs10886442 GRK5 1.038
rs10998780 ATP5MC1P7 0.704
Continued on the next page
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Table 14: Continued from the previous page.
SNP Gene∗ chol act gl ceraf alcohol
rs11017821 TCERG1L 0.665
rs11198590 CACUL1 -0.698 0.905 0.568
rs11200996 CCSER2 0.508
rs11259039 FRMD4A 1.174
rs1219508 RPS15AP5 -0.787
rs12265854 SLC16A12 0.681 -0.494
rs12269237 RF00017 0.684
rs12414552 TCERG1L 0.480
rs12764378 ARID5B -0.420
rs12767723 SLC25A18P1 0.638 -0.559
rs12775160 FOXI2 -0.762 0.893
rs1361709 PCDH15 -0.852
rs1395465 RN7SL63P 0.292
rs16916794 SLC39A12 -0.614 0.580 0.622
rs16920092 PLXDC2 -0.692
rs17094114 GFRA1 -0.676
rs17469499 KIAA1217 -0.527
rs2472737 RET 0.629
rs2577356 GFRA1 0.875
rs2784767 PLAC9 -0.569 0.537
rs2792708 GPAM 0.488
rs2900814 SNRPD2P1 -0.460
rs2926458 RNU6-463P -0.680
rs3763722 LARP4B -1.251 1.186
rs4411238 PRKG1 0.619
rs4747517 ITIH5 -1.257
rs4752432 PLPP4 0.956
rs4917817 PYROXD2 -0.626 0.630
rs4922535 GDF10 -0.601 -0.649
rs4934762 PCAT5 -0.640
rs4934858 NRP1 0.281
rs6482836 DOCK1 -0.773
rs7070789 GPAM -0.642
rs7072255 ANTXRLP1 0.723
rs7085788 RHOBTB1 -0.720
rs7086058 RN7SKP143 -0.507
rs716168 VTI1A -0.570
rs7894809 PCGF5 0.642
rs7895870 RN7SKP167 -0.867
rs7896554 NACAP2 1.097 -0.477
rs7917422 HTR7 0.794
Continued on the next page
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Table 14: Continued from the previous page.
SNP Gene∗ chol act gl ceraf alcohol
rs881726 GFRA1 0.933
∗ Genes that SNPs belong to or are the closest to.
Table 15: Analysis of the NHS T2D data using BL-SS.
SNP Gene∗ chol act gl ceraf alcohol
3.095 -2.406 -2.373 -1.716 -3.721
rs1041168 PLPP4 0.670
rs10508670 KIAA1217 0.773
rs10765059 TCERG1L 0.445
rs10829671 EBF3 -0.717
rs10884466 RNA5SP326 -0.528
rs10998780 ATP5MC1P7 1.195
rs11017821 TCERG1L 0.307
rs11198590 CACUL1 1.273
rs11200996 CCSER2 0.509
rs11202221 BMPR1A 0.954
rs11259039 FRMD4A 1.020
rs11594070 ATE1-AS1 -0.401
rs1194657 THAP12P3 0.681
rs12248205 CDH23 -0.938
rs12256982 ZMIZ1 0.152
rs12265854 SLC16A12 0.661 -0.830
rs12269237 RF00017 0.864
rs12412976 RPLP1P10 0.592 -0.590
rs12414552 TCERG1L 0.549
rs12414627 PNLIPRP1 -0.572
rs12764378 ARID5B -0.564
rs12767723 SLC25A18P1 1.062
rs12775160 FOXI2 -0.636
rs1361709 PCDH15 -0.729
rs1395465 RN7SL63P 0.562
rs1573137 SORCS3 0.869
rs16916794 SLC39A12 -0.430 0.862
rs16920092 PLXDC2 -0.508
rs17094114 GFRA1 -0.734
rs17469499 KIAA1217 -0.680
rs2384105 SNRPEP8 -0.738
rs2420979 TACC2 -0.629
rs2472737 RET 0.553
rs2577356 GFRA1 0.739
Continued on the next page
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Table 15: Continued from the previous page.
SNP Gene∗ chol act gl ceraf alcohol
rs2784767 PLAC9 -0.593 0.576
rs2792708 GPAM 0.568
rs2900814 SNRPD2P1 -0.157
rs2926458 RNU6-463P -0.527
rs3763722 LARP4B -1.002 1.151
rs4411238 PRKG1 0.461
rs4747009 LRRC20 1.016
rs4747517 ITIH5 -1.695
rs4752432 PLPP4 0.787
rs4917817 PYROXD2 -0.637 0.751
rs4934762 PCAT5 -0.771
rs4934858 NRP1 0.496
rs6482836 DOCK1 -0.899
rs7069001 WDFY4 -0.942
rs7070789 GPAM -1.154 -0.771
rs7077718 DNMBP -0.661
rs7085788 RHOBTB1 -0.721
rs7086058 RN7SKP143 -0.872
rs716168 VTI1A -0.662
rs7894809 PCGF5 0.828
rs7895870 RN7SKP167 -1.295
rs7896554 NACAP2 0.989
rs7917422 HTR7 0.663 1.306
rs7920351 TCERG1L -1.059
rs809836 LYZL1 1.109
rs881726 GFRA1 0.922
rs915216 DUSP5 1.102
∗ Genes that SNPs belong to or are the closest to.
Table 16: Analysis of the TCGA SKCM data using
RBSG-SS.
Gene clark stage age gender
0.834 0.228 -0.116 -0.183
AHNAKRS 0.107
ANKRD28 0.134 0.138
ASH2L -0.297
BTD -0.312
C1ORF140 -0.002 0.246 -0.083 -0.022 0.092
CD44 0.070
CHP1 0.107 0.045
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Table 16: Continued from the previous page.
Gene clark stage age gender
CXCL6 0.126 -0.120 -0.095
DLG6 0.113 -0.015 0.067 0.185 -0.142
DOK5 -0.066
ETNK2 0.152
FILIP1 -0.030
JADE1 -0.147
JPH4 0.115
KBF2 -0.032 0.182 0.034 -0.026
LRRN2 -0.061
MAGED4 -0.098 -0.020
NHSL2 -0.088
PITPNA 0.151 -0.051 -0.012 -0.033 0.008
SOX8 0.088 -0.212
TMEM145 0.048
TMEM159 0.160 -0.121 -0.042 0.189
WBSCR27 0.070 0.126
Table 17: Analysis of the TCGA SKCM data using RBL-
SS.
Gene clark stage age gender
0.926 -0.062 -0.011 0.388
AHNAKRS 0.084
ANKRD28 0.191 0.207
ASH2L -0.258
BAIAP2 0.043
BTD -0.309 -0.255
C1ORF140 0.129
C1ORF54 -0.102
CHP1 0.081 -0.111
CPXM1 0.005
CSNK2A2 -0.003
CYP1B1-AS1 0.104
DAP 0.036 -0.116
DLG6 0.242
ETNK2 0.109
FHL5 0.220
FILIP1 -0.016
GAMT 0.082
IL11RA -0.087
IQCK -0.090
Continued on the next page
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Table 17: Continued from the previous page.
Gene clark stage age gender
JADE1 -0.161
JPH4 0.159
KDM6B -0.142
LRFN2 0.096
MAGED4 -0.130
MAPE -0.191
MPD1 -0.078
NHSL2 -0.144 -0.306
PAX1 0.171 0.217
PBX2 0.141 0.130
PITPNA 0.161 -0.056
RNPEPL1 0.052
SLC12A5 -0.081
SOX8 0.140 -0.091
STPG1 0.184
TMEM145 0.222
TMEM159 0.123
TNFAIP1 0.283
TP53TG1 0.102 -0.063
WBSCR27 0.090 0.126
Table 18: Analysis of the TCGA SKCM data using BSG-
SS.
Gene clark stage age gender
0.487 0.163 0.048 0.087
AHNAKRS 0.120
ANKRD28 0.138
ARMC9 0.008
ASH2L 0.019 -0.194 -0.107
BTD -0.303 -0.138
C14ORF2 0.251
C1ORF140 0.100 0.024 0.029
CD44 0.125
CHP1 0.123
CPXM1 -0.047
CXCL6 0.032
DLG6 0.093 0.204 -0.061
DOK5 -0.052
ETNK2 0.094
FILIP1 -0.049
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Table 18: Continued from the previous page.
Gene clark stage age gender
GAMT -0.004
IL11RA -0.045
JADE1 -0.149
JPH4 0.110
KBF2 -0.077
LRRN2 -0.073
MAGED4 -0.122
MAPE -0.217
NHSL2 -0.026
PBX2 0.133 0.155
PHP1B -0.076
PITPNA 0.150 0.077 0.038 -0.039
SOX8 0.103 -0.148
STPG1 0.197
TMEM145 0.015 -0.045 0.147
TMEM159 0.140 0.113
TNFRSF4 0.077
TP53TG1 0.072
WBSCR27 0.015 0.092
ZFP62 -0.010
Table 19: Analysis of the TCGA SKCM data using BL-
SS.
Gene clark stage age gender
0.545 0.308 0.080 0.047
AHNAKRS 0.102
ANKRD28 0.180 0.134
ASH2L -0.185
BTD -0.386
C14ORF2 0.126
C1ORF140 0.199
CELSR2 0.112
CHP1 0.080
CPXM1 -0.067
CSNK2A2 -0.026
CYP1B1-AS1 0.104
DAP -0.139
DLG6 0.088 0.236
ETNK2 0.206 -0.089
FHL5 0.076
Continued on the next page
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Table 19: Continued from the previous page.
Gene clark stage age gender
FILIP1 -0.062
GAMT 0.058
IL11RA -0.056
IQCK -0.098
JADE1 -0.203
JPH4 0.101
KBF2 -0.089
KDM6B -0.173
LRFN2 0.109
LRRN2 -0.091
MAGED4 -0.113
MAPE -0.114
MPD1 -0.100
NHSL2 -0.035
PAX1 0.050
PBX2 0.126 0.072
PHP1B -0.054
PIP4K2C -0.101
PITPNA 0.193
PTP4A3 -0.138
RNPEPL1 0.171
SAA2 0.021 -0.058
SLC12A5 -0.112
SOX8 0.132 -0.084
TIE1 -0.093
TMEM145 0.188
TMEM159 0.174 0.181
TP53TG1 0.156 -0.030
WBSCR27 0.048 0.105
F Biological similarity analysis
We carried out an examination of the Gene Ontology (GO) biological processes which provide
us with a deeper insight on the differences of the markers identified by different methods. We
totally identified 77 unique genes using our proposed method along with three other methods
for the NHS data. We conducted the GO enrichment analysis using the R package GOSim
and found these genes involve in a total of 158 GO biological processes, the p-values of which
are smaller than 0.1 in the GO enrichment analysis. Then we divided the 158 processes into
four categories: positive regulation (P), negative regulation (N), regulation (R, without a
well-defined “direction”) and other (O). We computed the proportions of genes that involve
in the four categories of processes for each of the four methods. Similarly, for the TCGA
SKCM data, 109 genes were identified by our method along with three other alternative
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methods. GO enrichment analysis showed that they involve in 183 biological processes, with
p-values smaller than 0.1. The results for NHS and TCGA SKCM are provided in Figure 3,
which shows an obvious difference between our proposed method and the three alternatives
in both datasets.
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Figure 3: Gene Ontology (GO) analysis: proportions of genes that have the four categories
of processes with different approaches. Left: NHS data. Right: TCGA SKCM data.
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G Posterior inference
G.1 RBG-SS
G.1.1 Hierarchical model specification
yi = W
>
i α + E
>
i θ + U
>
i β + ν
− 1
2κ
√
uizi i = 1, . . . , n
ui|ν ind∼ ν exp (−νui) i = 1, . . . , n
zi
ind∼ N(0, 1) i = 1, . . . , n
ν ∼ Gamma (c1, c2)
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βj|φj, sj ind∼ φj NL (0, sjIL) + (1− φj)δ0(βj) j = 1, . . . , p
φj|pi0 ind∼ Bernoulli(pi0) j = 1, . . . , p
pi0 ∼ Beta (a0, b0)
sj|η ∼ Gamma
(
L+ 1
2
,
η
2
)
j = 1, . . . , p
η ∼ Gamma (d1, d2)
G.1.2 Gibbs Sampler
• ui|rest ∼ Inverse-Gaussian(µui , λui), where the shape parameter λui = 2ν, mean pa-
rameter µui =
√
2κ2
(yi−y˜i)2 and y˜i = yi −W>i α− E>i θ − U>i β.
• ν|rest ∼ Gamma (sν , rν), where the shape parameter sν = c1 + 3n2 and the rate param-
eter rν = c2 +
∑n
i=1 ui + (2κ
2)−1
∑n
i=1 u
−1
i y˜i
2.
• α|rest ∼ N(µα, Σα), where
µα = Σανκ
−2
n∑
i=1
u−1i Wi(yi − E>i θ − U>i β)
Σα =
(
νκ−2
n∑
i=1
u−1i WiW
>
i + Σ
−1
α0
)−1
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• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθνκ
−2
n∑
i=1
u−1i Ei(yi −W>i α− U>i β)
Σθ =
(
νκ−2
n∑
i=1
u−1i EiE
>
i + Σ
−1
θ0
)−1
• βj|rest ∼ ljN(µβj , Σβj) + (1− lj)δ0(βj) where
µβj = Σβjνκ
−2
n∑
i=1
u−1i Uij y˜ij
Σβj =
(
νκ−2
n∑
i=1
u−1i UijU
>
ij +
1
sj
IL
)−1
lj =
pi0
pi0 + (1− pi0)s
L
2
j |Σβj |−
1
2 exp
{
−1
2
‖Σ
1
2
βj
νκ−2
∑n
i=1 u
−1
i Uij y˜ij‖22
}
and y˜ij is defined as y˜ij = yi −W>i α− E>i θ − U>(j)β(j).
• The posterior of sj is
s−1j |rest ∼
Inverse-Gamma(
L+1
2
, η
2
) if βj = 0
Inverse-Gaussian(η,
√
η
‖βj‖22 ) if βj 6= 0
• pi0|rest ∼ Beta
(
a0 +
∑p
j=1 I{βj 6=0}, b0 +
∑p
j=1 I{βj=0}
)
• η|rest ∼ Gamma (sη, rη), where sη = p+p×L2 +d1 and the rate parameter rη =
∑p
j=1 sj
2
+
d2.
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G.2 RBL-SS
G.2.1 Hierarchical model specification
yi = W
>
i α + E
>
i θ + U
>
i β + ν
− 1
2κ
√
uizi
ui|ν ind∼ ν exp (−νui)
zi
ind∼ N(0, 1)
ν ∼ Gamma (c1, c2)
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βjl|φjl, sjl ind∼ φjl N (0, sjl) + (1− φjl)δ0(βjl) j = 1, . . . , p; l = 1, . . . , L
φjl|pi1 ind∼ Bernoulli(pi1) j = 1, . . . , p; l = 1, . . . , L
sjl|η ∼ Gamma
(
1,
η
2
)
j = 1, . . . , p; l = 1, . . . , L
pi1 ∼ Beta (a1, b1)
η ∼ Gamma (d1, d2)
G.2.2 Gibbs Sampler
• ui|rest ∼ Inverse-Gaussian(µui , λui), where the shape parameter λui = 2ν, mean pa-
rameter µui =
√
2κ2
(Yi−y˜i)2 and y˜i = yi −W>i α− E>i θ − U>i β.
• ν|rest ∼ Gamma (sν , rν), where the shape parameter sν = c1 + 3n2 and the rate param-
eter rν = c2 +
∑n
i=1 ui + (2κ
2)−1
∑n
i=1 u
−1
i y˜i
2.
• α|rest ∼ N(µα, Σα), where
µα = Σανκ
−2
n∑
i=1
u−1i Wi(Yi − E>i θ − U>i β)
Σα =
(
νκ−2
n∑
i=1
u−1i WiW
>
i + Σ
−1
α0
)−1
• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθνκ
−2
n∑
i=1
u−1i Ei(Yi −W>i α− U>i β)
Σθ =
(
νκ−2
n∑
i=1
u−1i EiE
>
i + Σ
−1
θ0
)−1
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• βjl|rest ∼ ljlN(µβjl , σ2βjl) + (1− ljl)δ0(βjl) where
µβjl = σ
2
βjl
νκ−2
n∑
i=1
u−1i Uijly˜ijl
σ2βjl =
(
νκ−2
n∑
i=1
u−1i U
2
ijl +
1
sjl
)−1
ljl =
pi1
pi1 + (1− pi1)s
1
2
jl(σ
2
βjl
)−
1
2 exp
{
−1
2
σ2βjl(νκ
−2∑n
i=1 u
−1
i Uijly˜ijl)
2
}
and y˜ijl is defined as y˜ijl = yi −W>i α− E>i θ − U>(jl)β(jl).
• The posterior of sjl is
s−1jl |rest ∼
Inverse-Gamma(1,
η
2
) if βjl = 0
Inverse-Gaussian(η,
√
η
β2jl
) if βjl 6= 0
• pi1|rest ∼ Beta
(
a1 +
∑
j,l I{βjl 6=0}, b1 +
∑
j,l I{βjl=0}
)
• η|rest ∼ Gamma (sη, rη), where sη = p×L+d1 and the rate parameter rη =
∑
j,l sjl
2
+d2.
G.3 RBSG
G.3.1 Hierarchical model specification
yi = W
>
i α + E
>
i θ + U
>
i β + ν
− 1
2κ
√
uizi
ui|ν ind∼ ν exp (−νui)
zi
ind∼ N(0, 1)
ν ∼ Gamma (c1, c2)
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βj|rj, ωjl ind∼ NL(0, Vj), where Vj = diag
{( 1
rj
+
1
ωjl
)−1
, l = 1, 2, . . . , L
}
rj, ωj1, . . . , ωjL|η1, η2 ∝
L∏
l=1
[
(ωjl)
− 1
2
(
1
rj
+
1
ωjl
)− 1
2
]
(rj)
− 1
2 exp
(
−η1
2
rj − η2
2
L∑
l=1
ωjl
)
η1, η2 ∝ η
p
2
1 η
pL
2 exp {−d1η1 − d2η2}
σ2 ∼ 1/σ2
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G.3.2 Gibbs Sampler
• ui|rest ∼ Inverse-Gaussian(µui , λui), where the shape parameter λui = 2ν, mean pa-
rameter µui =
√
2κ2
(Yi−y˜i)2 and y˜i = yi −W>i α− E>i θ − U>i β.
• ν|rest ∼ Gamma (sν , rν), where the shape parameter sν = c1 + 3n2 and the rate param-
eter rν = c2 +
∑n
i=1 ui + (2κ
2)−1
∑n
i=1 u
−1
i y˜i
2.
• α|rest ∼ N(µα, Σα), where
µα = Σανκ
−2
n∑
i=1
u−1i Wi(Yi − E>i θ − U>i β)
Σα =
(
νκ−2
n∑
i=1
u−1i WiW
>
i + Σ
−1
α0
)−1
• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθνκ
−2
n∑
i=1
u−1i Ei(Yi −W>i α− U>i β)
Σθ =
(
νκ−2
n∑
i=1
u−1i EiE
>
i + Σ
−1
θ0
)−1
• βj|rest ∼ N(µβj , Σβj) where
µβj = Σβjνκ
−2
n∑
i=1
u−1i Uij y˜ij
Σβj =
(
νκ−2
n∑
i=1
u−1i UijU
>
ij + V
−1
j
)−1
and y˜ij is defined as y˜ij = yi −W>i α− E>i θ − U>(j)β(j).
• r−1j |rest ∼ Inv-Gaussian(η1,
√
η1σ2
‖βj‖22 )
• ω−1jl |rest ∼ Inv-Gaussian(η2,
√
η2σ2
β2jl
)
• η1|rest ∼ Gamma (sη1 , rη1), where sη1 = p2+1 and the rate parameter rη1 =
∑p
j=1 rj
2
+d1.
• η2|rest ∼ Gamma (sη2 , rη2), where sη2 = p × L + 1 and the rate parameter rη2 =∑
j,l ωjl
2
+ d2.
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G.4 RBG
G.4.1 Hierarchical model specification
yi = W
>
i α + E
>
i θ + U
>
i β + ν
− 1
2κ
√
uizi i = 1, . . . , n
ui|ν ind∼ ν exp (−νui) i = 1, . . . , n
zi
ind∼ N(0, 1) i = 1, . . . , n
ν ∼ Gamma (c1, c2)
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βj|sj ind∼ NL (0, sjIL) j = 1, . . . , p
sj|η ∼ Gamma
(
L+ 1
2
,
η
2
)
j = 1, . . . , p
η ∼ Gamma (d1, d2)
G.4.2 Gibbs Sampler
• ui|rest ∼ Inverse-Gaussian(µui , λui), where the shape parameter λui = 2ν, mean pa-
rameter µui =
√
2κ2
(yi−y˜i)2 and y˜i = yi −W>i α− E>i θ − U>i β.
• ν|rest ∼ Gamma (sν , rν), where the shape parameter sν = c1 + 3n2 and the rate param-
eter rν = c2 +
∑n
i=1 ui + (2κ
2)−1
∑n
i=1 u
−1
i y˜i
2.
• α|rest ∼ N(µα, Σα), where
µα = Σανκ
−2
n∑
i=1
u−1i Wi(yi − E>i θ − U>i β)
Σα =
(
νκ−2
n∑
i=1
u−1i WiW
>
i + Σ
−1
α0
)−1
• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθνκ
−2
n∑
i=1
u−1i Ei(yi −W>i α− U>i β)
Σθ =
(
νκ−2
n∑
i=1
u−1i EiE
>
i + Σ
−1
θ0
)−1
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• βj|rest ∼ N(µβj , Σβj) where
µβj = Σβjνκ
−2
n∑
i=1
u−1i Uij y˜ij
Σβj =
(
νκ−2
n∑
i=1
u−1i UijU
>
ij +
1
sj
IL
)−1
and y˜ij is defined as y˜ij = yi −W>i α− E>i θ − U>(j)β(j).
• s−1j |rest ∼ Inverse-Gaussian(η,
√
η
‖βj‖22 )
• η|rest ∼ Gamma (sη, rη), where sη = p+p×L2 +d1 and the rate parameter rη =
∑p
j=1 sj
2
+
d2.
G.5 RBL
G.5.1 Hierarchical model specification
yi = W
>
i α + E
>
i θ + U
>
i β + ν
− 1
2κ
√
uizi
ui|ν ind∼ ν exp (−νui)
zi
ind∼ N(0, 1)
ν ∼ Gamma (c1, c2)
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βjl|sjl ind∼ N (0, sjl) j = 1, . . . , p; l = 1, . . . , L
sjl|η ∼ Gamma
(
1,
η
2
)
j = 1, . . . , p; l = 1, . . . , L
η ∼ Gamma (d1, d2)
G.5.2 Gibbs Sampler
• ui|rest ∼ Inverse-Gaussian(µui , λui), where the shape parameter λui = 2ν, mean pa-
rameter µui =
√
2κ2
(Yi−y˜i)2 and y˜i = yi −W>i α− E>i θ − U>i β.
• ν|rest ∼ Gamma (sν , rν), where the shape parameter sν = c1 + 3n2 and the rate param-
eter rν = c2 +
∑n
i=1 ui + (2κ
2)−1
∑n
i=1 u
−1
i y˜i
2.
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• α|rest ∼ N(µα, Σα), where
µα = Σανκ
−2
n∑
i=1
u−1i Wi(Yi − E>i θ − U>i β)
Σα =
(
νκ−2
n∑
i=1
u−1i WiW
>
i + Σ
−1
α0
)−1
• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθνκ
−2
n∑
i=1
u−1i Ei(Yi −W>i α− U>i β)
Σθ =
(
νκ−2
n∑
i=1
u−1i EiE
>
i + Σ
−1
θ0
)−1
• βjl|rest ∼ N(µβjl , σ2βjl) where
µβjl = σ
2
βjl
νκ−2
n∑
i=1
u−1i Uijly˜ijl
σ2βjl =
(
νκ−2
n∑
i=1
u−1i U
2
ijl +
1
sjl
)−1
and y˜ijl is defined as y˜ijl = yi −W>i α− E>i θ − U>(jl)β(jl).
• s−1j |rest ∼ Inverse-Gaussian(η,
√
η
β2jl
)
• η|rest ∼ Gamma (sη, rη), where sη = p×L+d1 and the rate parameter rη =
∑
j,l sjl
2
+d2.
50
G.6 BSG-SS
G.6.1 Hierarchical model specification
Y ∝ (σ2)−n2 exp
{
− 1
2σ2
n∑
i=1
(yi −W>i α− E>i θ − U>i β)2
}
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βj = V
1
2
j bj, where V
1
2
j = diag{ωj1, . . . , ωjL}
bj|φbj ind∼ φbj NL (0, IL) + (1− φbj)δ0(bj)
φbj|pi0 ind∼ Bernoulli(pi0)
pi0 ∼ Beta (a0, b0)
ωjl|φwjl ind∼ φwjl N+
(
0, s2
)
+ (1− φwjl)δ0(ωjl)
φwjl|pi1 ind∼ Bernoulli(pi1)
pi1 ∼ Beta (a1, b1)
s2 ∼ Inverse-Gamma (1, η)
σ2 ∼ 1/σ2
G.6.2 Gibbs Sampler
• α|rest ∼ N(µα, Σα), where
µα = Σα(σ
2)−1
n∑
i=1
Wi(yi − E>i θ − U>i β)
Σα =
(
1
σ2
n∑
i=1
WiW
>
i + Σ
−1
α0
)−1
• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθ(σ
2)−1
n∑
i=1
Ei(yi −W>i α− U>i β)
Σθ =
(
1
σ2
n∑
i=1
EiE
>
i + Σ
−1
θ0
)−1
51
• bj|rest ∼ ljN(µbj , Σbj) + (1− lj)δ0(bj) where
µbj = Σbj(σ
2)−1
n∑
i=1
V
1
2
j Uij y˜ij
Σbj =
(
1
σ2
n∑
i=1
V
1
2
j UijU
>
ijV
1
2
j + IL
)−1
lbj =
pi0
pi0 + (1− pi0)|Σbj |−
1
2 exp
{
− 1
2σ4
‖Σ
1
2
bj
∑n
i=1 V
1
2
j Uij y˜ij‖22
}
and y˜ij is defined as y˜ij = yi −W>i α− E>i θ − U>(j)β(j).
• ωjl|rest ∼ lwjl N+(µωjl , σ2ωjl) + (1− lwjl)δ0(ωjl) where
µωjl = σ
2
ωjl
(σ2)−1
n∑
i=1
bjlUijly˜ijl
σ2ωjl =
(
1
σ2
n∑
i=1
U2ijlb
2
jl +
1
s2
)−1
lwjl =
pi1
pi1 + (1− pi1)12s(σ2ωjl)−
1
2 exp
{
−σ
2
ωjl
2σ4
(
∑n
i=1 bjlUijly˜ijl)
2
}[
Φ
(
µωjl
σωjl
)]−1
and y˜ijl is defined as y˜ijl = yi −W>i α− E>i θ − U>(jl)β(jl).
• s2|rest ∼ Inv-Gamma
(
1 + 1
2
∑
j,l I{ωjl 6=0}, η +
1
2
∑
j,l ω
2
jl
)
• pi0|rest ∼ Beta
(
a0 +
∑p
j=1 I{βj 6=0}, b0 +
∑p
j=1 I{βj=0}
)
• pi1|rest ∼ Beta
(
a1 +
∑
j,l I{ωjl 6=0}, b1 +
∑
j,l I{ωjl=0}
)
• η is estimated with the EM approach used in the proposed method. For the gth EM
update η(g) = 1
E
η(g−1) [
1
s2
|Y ] .
• σ2|rest ∼ Inv-Gamma(n
2
,
∑n
i=1 y˜i
2
2
), where y˜i = yi −W>i α− E>i θ − U>i β.
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G.7 BGL-SS
G.7.1 Hierarchical model specification
Y ∝ (σ2)−n2 exp
{
− 1
2σ2
n∑
i=1
(yi −W>i α− E>i θ − U>i β)2
}
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βj|φj, σ2, sj ind∼ φj NL
(
0, σ2sjIL
)
+ (1− φj)δ0(βj) j = 1, . . . , p
φj|pi0 ind∼ Bernoulli(pi0) j = 1, . . . , p
pi0 ∼ Beta (a0, b0)
sj|η ind∼ Gamma
(
L+ 1
2
,
η
2
)
j = 1, . . . , p
η ∼ Gamma (d1, d2)
σ2 ∼ 1/σ2
G.7.2 Gibbs Sampler
• α|rest ∼ N(µα, Σα), where
µα = Σα(σ
2)−1
n∑
i=1
Wi(yi − E>i θ − U>i β)
Σα =
(
1
σ2
n∑
i=1
WiW
>
i + Σ
−1
α0
)−1
• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθ(σ
2)−1
n∑
i=1
Ei(yi −W>i α− U>i β)
Σθ =
(
1
σ2
n∑
i=1
EiE
>
i + Σ
−1
θ0
)−1
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• βj|rest ∼ ljN(µβj , σ2Σβj) + (1− lj)δ0(βj) where
µβj = Σβj
n∑
i=1
Uij y˜ij
Σβj =
(
n∑
i=1
UijU
>
ij +
1
sj
IL
)−1
lj =
pi0
pi0 + (1− pi0)s
L
2
j |Σβj |−
1
2 exp
{
− 1
2σ2
‖Σ
1
2
βj
∑n
i=1 Uij y˜ij‖22
}
and y˜ij is defined as y˜ij = yi −W>i α− E>i θ − U>(j)β(j).
• The posterior of sj is
s−1j |rest ∼
Inverse-Gamma(
L+1
2
, η
2
) if βj = 0
Inverse-Gaussian(η,
√
ησ2
‖βj‖22 ) if βj 6= 0
• pi0|rest ∼ Beta
(
a0 +
∑p
j=1 I{βj 6=0}, b0 +
∑p
j=1 I{βj=0}
)
• η|rest ∼ Gamma (sη, rη), where sη = p+p×L2 +d1 and the rate parameter rη =
∑p
j=1 sj
2
+
d2.
• σ2|rest ∼ Inv-Gamma(n+L
∑p
j=1 I{βj 6=0}
2
,
∑n
i=1 y˜i
2+
∑p
j=1(sj)
−1β>j βj
2
), where y˜i = yi−W>i α−
E>i θ − U>i β.
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G.8 BL-SS
G.8.1 Hierarchical model specification
Y ∝ (σ2)−n2 exp
{
− 1
2σ2
n∑
i=1
(yi −W>i α− E>i θ − U>i β)2
}
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βjl|φjl, σ2, sjl ind∼ φjl N
(
0, σ2sjl
)
+ (1− φjl)δ0(βjl) j = 1, . . . , p; l = 1, . . . , L
φjl|pi1 ind∼ Bernoulli(pi1) j = 1, . . . , p; l = 1, . . . , L
sjl|η ind∼ Gamma
(
1,
η
2
)
j = 1, . . . , p; l = 1, . . . , L
pi1 ∼ Beta (a1, b1)
η ∼ Gamma (d1, d2)
σ2 ∼ 1/σ2
G.8.2 Gibbs Sampler
• α|rest ∼ N(µα, Σα), where
µα = Σα(σ
2)−1
n∑
i=1
Wi(yi − E>i θ − U>i β)
Σα =
(
1
σ2
n∑
i=1
WiW
>
i + Σ
−1
α0
)−1
• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθ(σ
2)−1
n∑
i=1
Ei(yi −W>i α− U>i β)
Σθ =
(
1
σ2
n∑
i=1
EiE
>
i + Σ
−1
θ0
)−1
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• βjl|rest ∼ ljlN(µβjl , σ2βjl) + (1− ljl)δ0(βjl) where
µβjl = σ
2
βjl
(σ2)−1
n∑
i=1
Uijly˜ijl
σ2βjl = σ
2
(
n∑
i=1
U2ijl +
1
sjl
)−1
ljl =
pi0
pi0 + (1− pi0)s
1
2
jl(σ
2
βjl
)−
1
2 (σ2)−
1
2 exp
{
−σ
2
βjl
2σ4
(
∑n
i=1 Uijly˜ijl)
2
}
and y˜ijl is defined as y˜ijl = yi −W>i α− E>i θ − U>(jl)β(jl).
• The posterior of sjl is
s−1jl |rest ∼
Inverse-Gamma(1,
η
2
) if βjl = 0
Inverse-Gaussian(η,
√
ησ2
β2jl
) if βjl 6= 0
• pi1|rest ∼ Beta
(
a1 +
∑
j,l I{βjl 6=0}, b1 +
∑
j,l I{βjl=0}
)
• η|rest ∼ Gamma (sη, rη), where sη = p×L+d1 and the rate parameter rη =
∑
j,l sjl
2
+d2.
• σ2|rest ∼ Inv-Gamma(n+
∑
j,l I{βjl 6=0}
2
,
∑n
i=1 y˜i
2+
∑
j,l(s
−1
jl )β
2
jl
2
), where y˜i = yi−W>i α−E>i θ−
U>i β.
G.9 BSG
G.9.1 Hierarchical model specification
Y |α, θ, β, σ2 ∝ (σ2)−n2 exp
{
− 1
2σ2
n∑
i=1
(yi −W>i α− E>i θ − U>i β)2
}
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βj|ωjl, rj ind∼ NL(0, σ2Vj), where Vj = diag
{( 1
rj
+
1
ωjl
)−1
, l = 1, 2, . . . , L
}
rj, ωj1, . . . , ωjL|η1, η2 ∝
L∏
l=1
[
(ωjl)
− 1
2
(
1
rj
+
1
ωjl
)− 1
2
]
(rj)
− 1
2 exp
(
−η1
2
rj − η2
2
L∑
l=1
ωjl
)
η1, η2 ∝ η
p
2
1 η
pL
2 exp {−d1η1 − d2η2}
σ2 ∼ 1/σ2
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G.9.2 Gibbs Sampler
• α|rest ∼ N(µα, Σα), where
µα = Σα(σ
2)−1
n∑
i=1
Wi(yi − E>i θ − U>i β)
Σα =
(
1
σ2
n∑
i=1
WiW
>
i + Σ
−1
α0
)−1
• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθ(σ
2)−1
n∑
i=1
Ei(yi −W>i α− U>i β)
Σθ =
(
1
σ2
n∑
i=1
EiE
>
i + Σ
−1
θ0
)−1
• βj|rest ∼ N(µβj , Σβj) where
µβj = Σβj(σ
2)−1
n∑
i=1
Uij y˜ij
Σβj = σ
2
(
n∑
i=1
UijU
>
ij + V
−1
j
)−1
and y˜ij is defined as y˜ij = yi −W>i α− E>i θ − U>(j)β(j).
• r−1j |rest ∼ Inv-Gaussian(η1,
√
η1σ2
‖βj‖22 )
• ω−1jl |rest ∼ Inv-Gaussian(η2,
√
η2σ2
β2jl
)
• η1|rest ∼ Gamma (sη1 , rη1), where sη1 = p2+1 and the rate parameter rη1 =
∑p
j=1 rj
2
+d1.
• η2|rest ∼ Gamma (sη2 , rη2), where sη2 = p × L + 1 and the rate parameter rη2 =∑
j,l ωj
2
+ d2.
• σ2|rest ∼ Inv-Gamma(n+p×L
2
,
∑n
i=1 y˜i
2+
∑p
j=1 β
>
j V
−1
j βj
2
), where y˜i = yi −W>i α − E>i θ −
U>i β.
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G.10 BGL
G.10.1 Hierarchical model specification
Y ∝ (σ2)−n2 exp
{
− 1
2σ2
n∑
i=1
(yi −W>i α− E>i θ − U>i β)2
}
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βj|σ2, sj ind∼ NL
(
0, σ2sjIL
)
j = 1, . . . , p
sj|η ind∼ Gamma
(
L+ 1
2
,
η
2
)
j = 1, . . . , p
η ∼ Gamma (d1, d2)
σ2 ∼ 1/σ2
G.10.2 Gibbs Sampler
• α|rest ∼ N(µα, Σα), where
µα = Σα(σ
2)−1
n∑
i=1
Wi(yi − E>i θ − U>i β)
Σα =
(
1
σ2
n∑
i=1
WiW
>
i + Σ
−1
α0
)−1
• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθ(σ
2)−1
n∑
i=1
Ei(yi −W>i α− U>i β)
Σθ =
(
1
σ2
n∑
i=1
EiE
>
i + Σ
−1
θ0
)−1
• βj|rest ∼ N(µβj , σ2Σβj) where
µβj = Σβj
n∑
i=1
Uij y˜ij
Σβj =
(
n∑
i=1
UijU
>
ij +
1
sj
IL
)−1
and y˜ij is defined as y˜ij = yi −W>i α− E>i θ − U>(j)β(j).
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• s−1j |rest ∼ Inverse-Gaussian(η,
√
ησ2
‖βj‖22 )
• η|rest ∼ Gamma (sη, rη), where sη = p+p×L2 +d1 and the rate parameter rη =
∑p
j=1 sj
2
+
d2.
• σ2|rest ∼ Inv-Gamma(n+p×L
2
,
∑n
i=1 y˜i
2+
∑p
j=1(sj)
−1β>j βj
2
), where y˜i = yi −W>i α − E>i θ −
U>i β.
G.11 BL
G.11.1 Hierarchical model specification
Y ∝ (σ2)−n2 exp
{
− 1
2σ2
n∑
i=1
(yi −W>i α− E>i θ − U>i β)2
}
α ∼ Nq(0, Σα0)
θ ∼ Nk(0, Σθ0)
βjl|σ2, sjl ind∼ N
(
0, σ2sjl
)
j = 1, . . . , p; l = 1, . . . , L
sjl|η ind∼ Gamma
(
1,
η
2
)
j = 1, . . . , p; l = 1, . . . , L
η ∼ Gamma (d1, d2)
σ2 ∼ 1/σ2
G.11.2 Gibbs Sampler
• α|rest ∼ N(µα, Σα), where
µα = Σα(σ
2)−1
n∑
i=1
Wi(yi − E>i θ − U>i β)
Σα =
(
1
σ2
n∑
i=1
WiW
>
i + Σ
−1
α0
)−1
• θ|rest ∼ N(µθ, Σθ), where
µθ = Σθ(σ
2)−1
n∑
i=1
Ei(yi −W>i α− U>i β)
Σθ =
(
1
σ2
n∑
i=1
EiE
>
i + Σ
−1
θ0
)−1
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• βjl|rest ∼ N(µβjl , σ2βjl) where
µβjl = σ
2
βjl
(σ2)−1
n∑
i=1
Uijly˜ijl
σ2βjl = σ
2
(
n∑
i=1
U2ijl +
1
sjl
)−1
and y˜ijl is defined as y˜ijl = yi −W>i α− E>i θ − U>(jl)β(jl).
• s−1j |rest ∼ Inverse-Gaussian(η,
√
ησ2
β2jl
)
• η|rest ∼ Gamma (sη, rη), where sη = p×L+d1 and the rate parameter rη =
∑
j,l sjl
2
+d2.
• σ2|rest ∼ Inv-Gamma(n+p×L
2
,
∑n
i=1 y˜i
2+
∑
j,l s
−1
jl β
2
jl
2
), where y˜i = yi −W>i α−E>i θ−U>i β.
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